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ABSTRACT 
DELAYED ANESTHETIC PRECONDITIONING AND  
METALLOTHIONEINS-I + II: 
 
NOVEL MEDIATORS OF ANESTHETIC 
-INDUCED PROTECTION. 
 
 
 
MAY 2009 
 
SCOTT D. EDMANDS, B.A., WHITMAN COLLEGE 
 
M.A., SMITH COLLEGE 
 
Ph. D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by:  Dr. Adam C. Hall 
 
 
 
Ischemic injury is a common and debilitating outcome of natural illness and as a 
complication of commonly performed medical procedures.  Whereas naturally occurring 
ischemic insults are often the result of unpredictable events, such as in the case of stroke 
or heart attack, the risk of operative and perioperative ischemia is somewhat better 
characterized in the clinical setting.  Given the prevalence and severity of outcomes in 
ischemic injury, there is significant interest in developing better pharmacological and 
procedural approaches to improve patient outcomes. One approach that has shown 
significant promise in the laboratory setting, particularly in the context of planned 
medical procedures, is the use of delayed anesthetic preconditioning. Delayed anesthetic 
preconditioning is a phenomenon whereby a prior exposure to clinical concentrations of 
commonly used inhaled anesthetics, including isoflurane, induces the production of 
vii 
 
endogenous protective proteins that are able to provide robust protection against 
subsequent, potentially toxic, ischemic insults.  Although many aspects of delayed 
anesthetic preconditioning have been previously described, a complete understanding of 
preconditioning mechanism has yet to emerge. 
The studies described in this dissertation aim to further our understanding of 
molecular mechanisms involved in delayed anesthetic preconditioning.  In the first 
project, I used DNA microarray to identify genes that were differentially expressed in 
adult rat liver, kidney and heart following a clinically relevant exposure to the inhaled 
anesthetic isoflurane.  By selecting those genes that were differentially expressed in 
multiple tissues, I was able to identify a small group of interesting genes for further 
study.  In my second study, I chose from our list two related genes, metallothioneins I + 
II, to analyze for a role in anesthetic-mediated protection.  Using a combination of 
approaches, I was able to establish that metallotioneins I + II play an essential role in 
delayed anesthetic preconditioning.  In the final study of this dissertation I explore a 
possible role for metallothioneins I + II as sensor molecules, involved in detecting 
cellular oxidative stress. 
Taken together, these three studies represent an important contribution to our 
understanding of the mechanisms of delayed anesthetic preconditioning and how they 
might contribute to protecting against ischemic stroke. 
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CHAPTER 1 
INTRODUCTION 
 
Ischemia Reperfusion injury (IRI) is a common complication in both surgical and 
trauma patients that leads to high degree of morbidity and mortality in a wide range of 
organ systems including lung 1, heart 2, brain3, liver 4, kidney 4, and intestine 5.  In 
neurological tissue, ischemia-producing complications from neurosurgical, vascular and 
cardiac procedures can induce stroke, seizures, and neuropsychological deficits 3.   
Despite advances in our understanding of what causes it, ischemic stroke remains a 
serious complication of surgery.  For example, following coronary artery bypass grafting, 
recent studies show an incidence of stroke ranging from 1.6-5.2%, while coratid 
endarterectomy (CEA) carries a risk of 0.25% to 7% 3.  In the North American CEA trial, 
35% of stokes occurred during the procedure while the remainder occurred after the 
patient left the operating room.  Of these, just over half of the delayed events occurred 
within 24 hours of surgery 3.  Given this substantial rate of surgical complication, there is 
significant clinical interest in developing both procedures and pharmacological agents 
that are capable of either protecting or preconditioning tissues against the risk of 
ischemia-reperfusion induced injury.  One approach that has been gaining significant 
interest for its potential to protect against ischemic injury in a number of tissues is the 
phenomenon of delayed anesthetic preconditioning (APC) 3,6.  In delayed anesthetic 
preconditioning, a clinical dose of an inhaled anesthetic is sufficient to set in motion an 
array of endogenous cellular pathways that are able to defend tissues against potentially 
toxic ischemia for days following the initial preconditioning treatment 3.  However, 
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before detailing anesthetic preconditioning and possible mechanisms of protection, it’s 
useful to have a basic overview of ischemic damage and the pathways that are involved 
in order to better understand preconditioning. 
 
Biology of Ischemia-Reperfusion injury 
Although ischemic injury can occur in any tissue, this introduction focuses on 
ischemic injury in the brain, or ischemic stroke.  Ischemic stroke is the result of a 
temporary or permanent reduction in cerebral blood flow due to blockage of a major 
cerebral artery from thrombosis (originating locally) or embolism (originating 
elsewhere).  Reduced blood flow and concomitant reduction in glucose and oxygen 
delivery sets in motion a complex cascade of molecular and cellular events, which, if 
untreated, ultimately leads to cellular death 7.  In animal models of ischemic injury, such 
as middle cerebral artery occlusion (MCAO), and in human stroke, the ischemic lesion 
can typically be divided into two distinct regions (See Figure 1.1).  The core of the 
ischemic lesion is made up of the tissue immediately served by the occluded artery and 
receives blood flow that is 25% or less of normal flow7. Radiating out from the core is a 
region called the penumbra that, while not neurologically functional, maintains structure 
as it receives collateral perfusion (< 40% normal) from nearby blood vessels7. If blood 
flow is not restored within a few hours, evidence indicates that tissue in the penumbral 
region will ultimately die and become part of the core. 7,8. Injury and death pathways in 
the core and penumbra differ markedly 9.  In ischemic the core, due to a near complete 
lack of available energy, cell death proceeds primarily by necrosis while in the penumbra, 
cells die by a mixture of necrosis and apoptosis with apoptosis becoming more common 
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the greater the distance from the core 10. In the context of neuroprotection, there appears 
to be little that can be done to protect against the near complete failure of energy systems 
in the core, however, there is evidence that targeting the penumbra for protective 
treatments could have significant long-term benefits for improving patient outcomes10. 
Figure 1.2 shows a simplified overview of the molecular and cellular events 
involved in the ischemic cascade.  It is important to note that while the figure depicts a 
stepwise progression of ischemic injury, in reality many of the depicted events will 
overlap one another both spatially and temporally10.  Lacking energy stores of its own, 
the brain depends on a steady supply of oxygen and glucose to undergo mitochondrial 
oxidative-phosphorylation for the production of ATP.  Therefore, attenuation of blood 
flow leads to rapid depletion of energy substrates for mitochondrially produced ATP, 
particularly oxygen and glucose, triggering a conversion to anaerobic glycolysis.   
Anaerobic glycolysis, with a resultant increase in cellular lactate, promotes increased 
reactive oxygen species (ROS) production and inhibition of cellular protein synthesis that 
may contribute to ischemic injury10.  Despite the energetic switch to anaerobic 
metabolism, ATP levels fall rapidly in the core of the ischemic lesion11.  Decreased ATP 
levels cause ionic gradients normally maintained by Na+/K+- ATPases and Ca2+/H+-
ATPase pumps to dissipate, leading to neuronal and glial depolarization 12,13.  This 
situation is further compounded by the reversal of Na+/Ca2+ transporters 14.  
Depolarization of neuronal and glial membranes triggers voltage dependent calcium 
channels to open, facilitating an influx of extracellular calcium which, in turn, leads to 
the release of excitatory neurotransmitters, including glutamate.13.  Accumulation of 
extracellular glutamate causes the ionotropic receptors N-methyl-D-aspartic acid 
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(NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), to open channels for Na+/Ca2+ and Na+ respectively, compounding 
calcium overload and promoting cellular edema respectively12.  Furthermore, 
release of Ca2+ via an IP3 –dependent pathway through activation of metabotropic 
glutamate receptors from organelles including endoplasmic reticulum, 
mitochondria, synaptic vesicles and Ca2+ binding proteins may further increase 
intracellular Ca2+ levels10. 
Increased intracellular Ca2+ plays an important role in cerebral ischemic 
injury by triggering the activation of an array of Ca2+ -dependent enzymes 
including protein kinase C, phospholipase A2, phospholipase C, cyclooxygenase, 
calcium-dependent nitric oxide synthase, calpain, proteases and endonucleases10.  
These events in turn result in the production of cytotoxic products including ROS, 
reactive nitrogen species (RNS)  and leukotrienes which, as discussed below, play 
an important role in ischemic damage10. 
ROS are generated by multiple pathways involved in the ischemic cascade 
and, in turn, contribute significantly to ischemic injury.  ROS are produced by 
inhibition of the oxidative phosphorylation machinery due to ionic imbalances in 
the mitochondria, as part of enzymatic processes such as the cyclooxygenase-
dependent conversion of arachidonic acid to prostanoids, by the degradation of 
hypoxanthine and by increased cellular lactate10. Furthermore, inflammation can 
significantly elevate local ROS and RNS levels15.   ROS react with and oxidize cellular 
lipids, proteins, and DNA, leading to dysregulation of cellular processes, 
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perturbations to ion homeostasis and interruption of normal cell signaling12,15,16.  
Ultimately, if ROS damage accumulates, it will eventually trigger cellular apoptosis 17.  
At the brain structure level, damage to cellular membranes by ROS contributes to the 
breakdown of the blood/brain barrier and promotes cerebral edema 16.   
Rapid Ca2+ influx along with increased ROS levels rapidly induces the 
upregulation and activation of a number of pro-inflammatory transcription factors 
including NF-Kappa B, hypoxia inducible factor 1 (HIF-1) and STAT313.  
Activation of these factors, leads to increased production of inflammatory 
cytokines including TNF-alpha and IL-1beta, and  inflammation related enzymes 
including iNOS and COX-213.  Ischemia also leads to increased expression of 
vascular adhesion molecules such as ICAM-1 and selectins in local vascular 
tissue, thereby increasing numbers of  neutrophils, macrophages, and monocytes at 
the site of injury within hours of the original insult.  The pathogenic role of 
immune cells at the site of injury is a subject of debate10.  Macrophages and 
microglia may be beneficial through their roles in tissue remodeling. However, 
activated phagocytes produce large quantities of ROS and RNS that may further 
increase the oxidative stress of the tissue and contribute cellular damage12,13,16. The 
rate and severity of cellular damage are dependent on the degree of blood flow 
attenuation.  In the core, where blood flow in the lowest, these events occur rapidly, 
however in the penumbra the progression of ischemic injury will play out over the course 
of days 13. 
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Depending on the severity of the initial ischemic insult, restoration of blood 
supply alone may not be sufficient to rescue affected tissues from injury 18. Indeed, 
disruption of normal energy pathways due to dysregulated pathways, ionic imbalances 
and cellular damage, the return of higher glucose and oxygen levels can lead to large 
increases in toxic ROS stemming both from inefficient mitochondrial oxidative 
phosphorylation 19 and from the energetic switch to the ROS producing NADPH oxidase 
pathway 18. These increases in ROS upon reperfusion lead to further oxidation of cellular 
proteins, lipids and DNA that can, in turn, trigger cellular apoptotic and necrotic 
pathways13. The complexity and number of pathways involved in the cellular response to 
ischemia makes treatment extremely challenging10.  In the context of neuroprotective 
treatments, such as delayed anesthetic preconditioning, the aim is to control the degree of 
these potentially toxic pathways such that cells are ultimately able to return to normal 
metabolism following the reinstatement of a normal blood supply. 
 
Treatment of ischemic stroke 
 Experimental animal models of focal ischemia have been developed in recent 
decades and have provided the basis for most of our understanding of the mechanisms 
involved in cerebral ischemia.  From these models, two main approaches have emerged 
for the treatment of ischemic stroke:  recanalization and neuroprotection 10.   
Recanalization involves the clearing of the arterial blockage by either surgical or 
pharmacologic means. Mechanical recanalization, using a mechanical embolectomy 
device to clear the blockage has shown positive early results, but is not yet widely used 
for treatment 20. Currently the recombinant tissue-type plasminogen activator (rt-PA) is 
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the only approved pharmacological treatment for acute ischemic stroke when 
administered within three hours after the onset of symptoms21.  While somewhat 
effective, only a small number (1-8.5%) of hospitalized patients receive rt-PA treatment 
due to the short window for treatment, the necessity for computed tomography scan and 
other exclusions 10,22.  
 Neuroprotection, on the other hand, complements recanalization with the 
aim of protecting the penumbral tissue and preventing growth of the ischemic core until 
normal blood flow can be restored10.  This approach arises from evidence, noted above, 
that reperfusion alone is not sufficient to prevent the progression of the ischemic lesion10.  
Numerous potentially neuroprotective agents that include glutamate release inhibitors, 
NMDA and AMPA antagonists, free radical scavengers, calcium channel blockers and 
chelators, and NO antagonists, have been directed at the various harmful steps of the 
ischemic cascade with the intent of preventing or delaying damage until homeostasis can 
be restored10.  However, though many substances have shown promise in vitro studies or 
in animal models of experimental stroke, the majority of agents have failed in clinical 
models.  Reasons for this are unclear and are likely due to multiple variables including 
experimental design, small sample sizes and heterogeneity of the clinical population10.  It 
may be too, that the treatment of any one pathway may be insufficient to for cellular 
protection, especially when so many pathways are affected through the ischemic cascade.  
In support of this, recent preclinical data suggest that approaches utilizing multi-drug 
combinations might have greater clinical effectiveness than those targeting individual 
agents 23. Given the overall lack of effective measures against ischemic damage, delayed 
preconditioning has arisen as a potentially useful therapeutic intervention. A central 
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benefit of the preconditioning approach is that preconditioning, by its nature, induces 
endogenous proteins that address multiple important points in the ischemic cascade (See 
mechanism section below).  By improving our understanding of preconditioning 
mechanisms, there is promise that therapies that are able to harness the power of these 
pathways will lead to improved patient outcomes.  
 
Introduction to general anesthetic agents 
General anesthetics comprise a wide range of structurally diverse molecules that 
are broadly categorized as volatile anesthetics, anesthetic gases, alcohols and intravenous 
agents (see Figure 1.3 for structures of these agents).  Most general anesthetics will 
effectively produce unconsciousness/hypnosis, immobility, and amnesia along with 
varying degrees of analgesia, muscle relaxation and depression of autonomic reflexes 24. 
Because general anesthetics vary in their ability to confer all of these functions, modern 
anesthesia typically supplements general anesthetics with analgesics and neuromuscular 
blockers 24. General anesthetic agents are thought to exert their anesthetic properties 
largely through positive or negative allosteric modulation of agonist activity at pre- and 
post-synaptic ligand-gated ion channels, though voltage-gated ion channels and g-protein 
coupled receptors may also play a role24.  In simpler form, anesthetics induce 
unconsciousness by blocking the propagation of neuronal action potentials either by 
inhibiting pre-synaptic excitatory transmitter release or by strengthening post-synaptic 
inhibitory response and thus blocking the excitation of the post-synaptic neuron. While 
all classes of general anesthetics are considered to be effective at inducing anesthesia, 
currently only volatile anesthetics, especially the halogenated ethers including isoflurane, 
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halothane, sevoflurane and desflurane, are thought to induce delayed anesthetic 
preconditioning. 19,25.  The mechanisms by which these anesthetics induce delayed 
preconditioning are likely distinct from those by which they induce unconsciousness and 
will be discussed below 26,27.   
 
Background of Preconditioning 
Preconditioning is an important biological phenomenon where exposure to a sub-
lethal stressor including heat stress, exercise, global or focal ischemia, inflammation, or 
exposure to an inhaled general anesthetic 28,29, can induce endogenous pathways that are 
able to protect against a subsequent, more severe ischemic insult 19.  Preconditioning 
typically manifests in at least two distinct temporal windows.  Early protection, also 
called “classical preconditioning” begins almost immediately following the 
preconditioning stimulus and dissipates after 1-2 hours 30.  In this type of 
preconditioning, protection is derived primarily from post-translational modifications to 
existing proteins 31.  Many of the pathways in classical preconditioning appear to 
converge on mitochondrial targets and include activation of phosphoinositide-3-kinase, 
protein kinase C, endothelial nitric oxide synthase, glycogen synthase kinase 3beta, and 
p38 mitogen-activated protein kinases.  Activation of these signaling molecules leads to 
changes to key mitochondrial proteins resulting in altered metabolism and reduction in 
cellular death31.  By contrast, delayed preconditioning appears to rely on de novo protein 
synthesis in order for protection to emerge.  As a result, protection begins later, 12-24 hrs 
following the preconditioning stimulus, and can provide protection lasting several days32-
34
. The remainder of this dissertation will concern itself with delayed preconditioning. 
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The idea that endogenous pathways could be harnessed in order to protect against 
hypoxia and ischemia dates back more than six decades. Noble, in 1943, first proposed 
that brief bouts of global ischemia might protect the entire organism and improve brain 
function during more extreme hypoxia 19. Janoff in 1964, examining changes to rabbit 
lysomal proteins following shock, coined the term “preconditioning” to denote sublethal 
stimulation that leads to later protection 35.  Two decades later, in the first reported 
clinical test of classical, or early ischemic preconditioning (IPC), Murry, in 1986, 
reported that brief, non-injuring bouts of ischemia protected canine heart against more 
protracted, potentially lethal ischemia 30. Finally, in the first report of delayed IPC, 
Kitagawa in 1990, demonstrated that short periods of global ischemia in gerbil were 
protective against more potent ischemia 1-2 days following the preconditioning regimen 
36
.  
While these early reports of preconditioning all used ischemia as the 
preconditioning agent, Kersten et al., in 1997, demonstrated anesthetic-induced classical 
preconditioning against ischemia-reperfusion injury in canine heart using the inhaled 
anesthetic isoflurane 29. Only very recently, in 2004, did Tanaka demonstrate that an 
inhaled anesthetic (again isoflurane) could induce delayed protection against the acute 
effects of ischemia in rabbit heart in a manner similar to that reported in regards to 
delayed ischemic preconditioning 37.  The work of Kersten and Tanaka has been 
supported and expanded upon by numerous studies in both animal models and through 
clinical studies 6,31,38. Although numerous studies showed anesthetic-induced protection 
against the acute effects of ischemia, ie. the tissue damage immediately following the 
ischemic insult, there remained questions as to the long-term benefits of delayed 
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preconditioning both in terms of tissue health and in terms of functional outcomes 6.  This 
question was recently addressed in a study where rats preconditioned with isoflurane and 
subjected to middle cerebral artery occlusion showed better histological and neurological 
outcomes at one month compared to non-preconditioned controls 39, thereby confirming 
that delayed preconditioning can improve long-term as well as acute outcomes in an 
animal model.   
Since Tanaka’s first report of isoflurane-induced delayed preconditioning in 
rabbit cardiac tissue, inhaled anesthetics have also been shown to induce endogenous 
protection in a range of other tissues including brain 40, spinal cord 41, liver 42, skeletal 
muscle  43, and immune cells 44.  In addition to supporting the hypotheis that inhaled 
anesthetics can induce protection, these studies support Noble’s 1943 hypothesis that 
anesthetic preconditioning (although he envisioned hypoxia as the preconditioning agent) 
might be able protect the whole of the organism against ischemic injury.  Taking an even 
broader view, a very interesting characteristic of delayed anesthetic preconditioning is 
that it appears to be conserved in a wide range of organisms including rabbit33, rat40, 
mouse45, gerbil36, and human44. Isoflurane has even recently been reported to effectively 
precondition the invertebrate Caenorhabditis elegans (C. elegans) against hypoxic injury, 
suggesting a fundamentally conserved cellular response to certain types of stress-- a 
property that we exploited to the inform data analysis in our first study (See Chapter 2; 
Methods)46.   
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Current understanding of mechanisms involved in delayed anesthetic 
preconditioning. 
The mechanisms by which inhaled anesthetics induce anesthesia are likely distinct 
from those that induce preconditioning.  Although the mechanisms of anesthetic 
induction of preconditioning are far from clear, they almost certainly rely on a transient 
increase in reactive oxygen and nitrogen species 47.  Recent studies suggest that inhaled 
anesthetics may initiate APC through ROS production by inhibiting the mitochondrial 
electron transport chain at complex I, III or V26,27,48, leading to an increase in cellular 
levels of ROS including the oxygen radical, superoxide (.O2)26,49.  The RNS nitric oxide, 
produced by endothelial nitric oxide synthase and/or inducible nitric oxide synthase, is 
also widely reported to be involved in the induction of delayed anesthetic preconditioning 
47,50
.   Though the specifics are lacking, ROS and RNS are thought to act as signaling 
molecules that trigger the production of other proteins involved in cellular protection, eg., 
superoxide dismutase, catalase, and hexokinase-2, 19,47.    
As described above, ischemic injury proceeds via a complex pathway involving a 
number of molecular players and pathways.  Interestingly, in addition to NO and .O2  
described above, many of these molecular players and pathways involved in the ischemic 
cascade are the same as those described in relation to delayed anesthetic preconditioning 
(Figure 1.4) 19.  These include:  transcription factors (STAT3 51, NFKB 50), inflammatory 
mediators (COX-2 37, iNOS, 50, eNOS 52), Antioxidants (Mn-SOD 53), ion channels, and 
other cellular enzymes (12-lypoxygenase 54,) Kinases (P13Kinase 55), mediators of  
apoptosis (Apaf1 46), and mitochondrial K(ATP) channel proteins (Vdac 56, and  K+-ATP 
channels 57,58).  Although some of the details of delayed preconditioning have been 
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described, our understanding of how these molecules interact with one another to confer 
protection is as yet incomplete.  A better understanding of the molecular players and the 
interactions that they have with one another will be essential for us to understand how 
anesthetic-induced protective measures work and how they might be better utilized for 
clinical protection against ischemia. 
Finally IPC and APC appear to protect via similar mechanisms.  Indeed a recent 
survey of mechanisms involved in delayed preconditioning suggest that there is 
significant similarity, if not identity in the pathways ascribed to preconditioning, 
regardless of the source of preconditioning stimulus19. Though both APC and IPC have 
been shown to protect in the clinical setting, APC has been gaining interest due to the 
ease with which it can be administered and to the increased safety of APC over IPC 59, 60 
2
. For this reason, we chose to focus our efforts on the mechanisms of delayed anesthetic 
preconditioning. 
       In the chapters that follow, we describe three studies aimed at furthering our 
understanding of the phenomena of delayed anesthetic preconditioning. In Chapter 1, we 
describe the use of DNA microarray to identify previously unidentified anesthetic-
regulated genes with the potential for involvement in anesthetic preconditioning.   In the 
second chapter, we selected metallothioneins I + II, two of the genes identified in Chapter 
1, and assessed their involvement in delayed anesthetic preconditioning.  Finally, in 
Chapter 3, we examine how metallothioneins I + II fit in to what is already known about 
the mechanism of delayed preconditioning.   Specifically, we ask if metallothioneins 
might act as sensors/transducers of oxidative stress during preconditioning.  Taken 
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together, these three studies represent an important contribution to our understanding of 
the mechanisms of delayed anesthetic preconditioning. 
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Figure 1.1.  Cartoon of ischemic lesion. The core of the ischemic lesion (light grey) is 
made up of the area immediately served by the occluded artery and is comprised of dead 
or dying cells.  Radiating out from the core is the penumbra which is served by collateral 
blood flow from nearby blood vessels.  Penumbral tissue, because of it’s potential to 
survive if blood flow is restored, is the target of neuroprotective approaches to ischemic 
injury. Figure adapted from: Acute Ischemic Stroke: New Concepts of Care© 
1998-1999 Genentech Inc.  
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Figure 1.2.  The ischemic cascade.  A.)  Normal cell:  With no blockages, energy 
substrates oxygen and glucose are delivered in the amounts needed for normal cellular 
function.  This allows ATP requirements to be met and energy requiring processes such 
as maintenance of ion gradients continue normally.  B.)  Shortly following arterial 
occlusion, glucose and oxygen levels drop, leading to rapidly diminished ATP levels.  
Low ATP levels causes the failure of Na+/K+-ATPases and the dissipation of membrane 
potential.  C.)  Drop in membrane potential triggers the opening of voltage dependent 
Ca2+ channels leading to massive influx of extracellular Ca2+.  This in turn causes 
glutamate to be exported where it accumulates in the extracellular space.  There it 
interacts with NMDA and AMPA to promote the entry of even more Ca2+ and Na+ into 
the cell.  Increased Ca2+ can inhibit mitochondrial respiration further, leading to increased 
ROS.  Ca2+ will also activates a variety of cellular enzymes that can lead to cellular 
damage.  Finally, Ca2+ along with increased ROS and RNS activate transcription factors 
that code for greater numbers of the enzymes already described as well as inflammatory 
cytokines and the upregulation of vascular adhesion molecules that will facilitate the 
arrival of activated phagocytes to the site of the injury.  D.)  Within hours of the initial 
injury, activated phagocytes and microglia arrive to the site of injury where they produce 
large quantities of reactive oxygen and nitrogen species.  They may also play a protective 
role by assisting in tissue remodeling and repair. 10,11,13 
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Figure 1.3.  Chemical structures of selected general anesthetics.  In the context of 
delayed preconditioning, the halogenated ethers including halothane, enflurane, 
sevoflurane and isoflurane have thus far proven most effective.  From Krasowski and 
Harrison 1999 24. 
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Figure 1.4.  Reported molecular players in delayed anesthetic preconditioning.  
Previously reported molecular participants are overlayed on figure of the ischemic 
cascade.  Red stars indicate molecules or pathways that have been reported to be involved 
both in ischemic injury and in preconditioning-mediated protection from ischemia. 
Anesthetic preconditioning has been reported to be mediated by: 1.) Modulation of 
mitochondrial K+-ATP channels 58. 2.) Scavenging of ROS 47,61.  3.) Regulation through 
STAT351. 4.) Induction of NF-kappa B50,62. 5.) Induction of HIF-163 6.) Increases in 
COX-2 activity37. 7.)  Modulation of phospholipases 64. 8.) Increases in production of 
nitric oxide by endothelial and/or inducible NOS 50,52. 9.) Modulation of TNF-alpha and 
IL-1beta levels65.  10.) Modulation of ICAM-1 and selectins expression 66 and 11.) 
Modulation of inflammation 67 
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CHAPTER 2 
IDENTIFICATION OF GENES DIFFERENTIALLY 
REGULATED IN RAT LIVER KIDNEY AND HEART FOLLOWING 
ISOFLURANE EXPOSURE 
 
Introduction 
For our initial study, we employed DNA microarray to identify novel anesthetic-
regulated genes following a clinical exposure to the inhalational anesthetic agent, 
isoflurane.  As a focus for our search we considered recently reported observations of 
ischemic injury and of anesthetic preconditioning to inform our experimental design and 
our data analysis.  Firstly, ischemic injury proceeds via a complex cascade of molecular 
events involving a number of ontological pathways such as the disruption of energy 
pathways, modulation of cell death pathways, dissipation of ion gradients and 
enhancement inflammatory processes 11.  Furthermore, studies have shown that genes 
involved in delayed APC target a number of different ischemia-related pathways 
(including iNOS 40, MT I + II 45, COX-2 37, and mitochondrial/sarcolemmal K+/ATP 
channels58).  Many studies have considered individual molecular and cellular pathways 
involved in protection against ischemia, however given the complexity of ischemic 
injury, we hypothesize that there are additional protective elements yet to be revealed. 
Furthermore, we noted that the protection provided by anesthetic preconditioning 
is a widely reported phenomenon and has been described in multiple organisms (mouse45, 
rat40, rabbit37, and human 38)  and tissues (heart37, brain40, skeletal muscle 43, kidney 
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68spinal chord41).  The concept that preconditioning may be a basic response to 
environmental stress is supported by a recent study by Jia and Crowder, describing 
isoflurane and halothane preconditioning in C. elegans2,46.  Thus, we hypothesized 
that by selecting genes differentially regulated in multiple tissues, we might 
identify genes involved in a general mechanism for preconditioning.   
 
Methods 
Animal Care 
Male Spraque-Dawley rats were acquired from Jackson Laboratories (250 and 
300 grams; Bar Harbor, ME) and allowed to acclimatize for two weeks prior to 
experiments.  Animals were maintained under a standard 12/12 light/dark cycle at room 
temperature and given access to food and water ad libitum. Animals were housed and all 
experiments carried out with protocols approved by Smith College Institutional Animal 
Care and Use Committee (Northampton, MA, USA) according to the Guide for the Care 
and Use of Laboratory Animals (National Institutes of Health, 1996). 
 
Arrays 
Rat specific DNA microarrays were obtained from the Rutgers Neuronal Gene 
expression Lab (NGEL; Piscataway, NJ).   Briefly, each array was constructed from a 
collection of 4967 probes representing approximately 4900 genes printed onto a poly-L-
lysine slide.  Probes were 65-70 nucleotides in length and were designed to optimize 
melting temperature and to minimize homology between probes.  Further information 
about these arrays can be found at the web site http://www.ngelab.org. 
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Isoflurane Exposure and Tissue Collection 
Animals receiving isoflurane treatment were placed in an induction chamber and 
induced with 3% isoflurane/97% medical grade air (vol/vol) until loss of righting reflex 
(2-3 minutes).  Anesthesia was then maintained at 2% isoflurane/98% air ~1.5 MAC 
(minimum alveolar concentration) for the remainder of the 90 minute exposure period.  
Body temperature was maintained at 37˚C throughout the treatment using heated gel 
packs and oxygen levels were monitored using a model V3304 pulse oximeter (Surgivet; 
Waukesha, WI).  Animals were observed to maintain > 95% oxygen saturation at all 
times.  Upon completion of the anesthetic exposure, test animals were immediately 
sacrificed by decapitation.  Samples from liver, kidney cortex and heart ventricle were 
collected and homogenized with a Polytron homogenizer (Brinkmann; Westbury, NY) in 
ice cold Trizol (Invitrogen; Carlsbad, CA). Because stress has been demonstrated to 
influence gene expression 69, control animals were maintained in their cages until the 
time of sacrifice.  Each control animal was handled gently and then rapidly decapitated.  
Tissue was processed in the same manner as test animals. Tissue/Trizol homogenates 
were stored at –20˚C until further processing.  All animals were sacrificed during the 
same daily 5hr window in order to diminish confounding factors from diurnal variations 
in gene expression 70. 
 
RNA Preparation 
Total RNA was isolated from Trizol/tissue homogenate by adding chloroform and 
performing a phase extraction.  The aqueous phase was mixed with ethanol 1:3 v/v and 
added to an Rneasy column (Qiagen: Valencia, CA). Manufacturer instructions were 
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followed for column washing and elution of RNA.  Purified RNA was quantified using a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies; Rockland, DE).  All 
samples yielded A260/A280 ratios between 1.9 and 2.1.  Isolated RNA was stored at –80˚C 
until further use.  The same RNA preparations were used for both microarray 
experiments and subsequent QRT-PCR verification of selected genes. 
 
Experimental Design 
For each tissue, RNA from an isoflurane-treated animal was competitively 
hybridized against control RNA from a pool comprised of equal amounts of RNA from 8 
control individuals 71.  For each tissue, this experiment was performed twice using the 
same labeling schema, and a third time reversing the labeling schema as a dye-flip 
control to ensure no dye-specific artifacts.  These three experiments were repeated for 
each of 3 experimental animals, for a total of  9 arrays per tissue.  
 
Target Labeling and Hybridization 
Microarray targets were prepared using the Genisphere 350 dendrimer labeling 
system according to manufacturer instructions (Genisphere, Inc.; Hatfield, PA) 72.  
Briefly, 2.5µg of isoflurane-treated and pooled control RNA were reverse-transcribed to 
cDNA in separate tubes using Superscript II (Invitrogen), and oligo d(T)18 primers 
containing unique, label-specific capture sequences. Samples were then alkaline 
hydrolyzed to destroy residual RNA.  Control and test tagged cDNAs were mixed, 
applied to arrays and sealed in watertight chambers (GeneMachines; Ann Arbor, MI), and 
allowed to hybridize for 48-72 hrs in a waterbath at 55˚C.  Arrays were washed one time 
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for 10 min (2X SSC, 55˚C), followed by two washes for 10 min (0.2X SSC, room 
temperature).  Arrays were then spin dried prior to labeling.  Hybridized arrays were 
labeled with fluorescent-labeled dendrimer and incubated 2 hrs at 61˚C.  Labeled arrays 
were washed and dried as described above and scanned using an Axon GenePix 4100 
scanner and GenePix 4.0 software (Axon Instruments; Union City, CA). 
 
Data Analysis 
Scanned array images were processed using Genepix 4.0 (Axon Instruments).  
Spots were eliminated if the signal to noise ratio of the spot fell below 2.0.  Statistical 
analysis of each tissue group was performed using G-Processor (version 3.1, Zhong Guan 
(http://bioinformatics.med.yale.edu).  This package performs a Lowess normalization 
71and yields a differential expression ratio along with a Student’s t-test p-value for each 
probe.  For each tissue, the gene list was screened for statistical significance in Excel 
(version 11.5.3 for MacIntosh ; Microsoft, Redmond, WA) using the following criteria: 
for each gene selected,  p-value ≤ 0.05, spot data were valid for ≥ 7 of the 9 arrays and 
level of differential expression was ≥ 1.2 compared to control.  The final list of 
“interesting genes” was compiled by choosing genes that were differentially expressed in 
more than one tissue and whose expression pattern (up or down) was consistent in the 
different tissues. 
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QRT-PCR  
In order to verify results from our microarray, three of the highly regulated genes 
from the liver array were selected for verification by quantitative reverse-transcriptase 
polymerase chain reaction (QRT-PCR). See Table 1 for primer and probe sequences.   All 
primer/probe sets were acquired from Integrated DNA technologies (IDT Inc., Coralville, 
IA). Each QRT-PCR reaction was carried out in a single tube on an Applied Biosystems 
7700 “Taqman” instrument (Applied Biosystems; Foster City, CA).  The QRT-PCR 
reaction mix was comprised of 1X PCR buffer (Invitrogen, Carlsbad, CA), 6mM MgCl2, 
0.67 mM each dinucleotide, 6.75 pmols each of forward and reverse primers, 100 nM 
FAM/TAMRA probe, 1.5 units Superase-in (Ambion; Austin, TX), 15 units Superscript 
II (Invitrogen), 0.75 units Platininum Taq Polymerase (Invitrogen) to a final volume of 
15µl.  Each reaction was run one cycle of  30’ at 42˚, 1 cycle of 3’ at 95˚ and 40 cycles of 
1’ at 60˚ and 20” at 95˚. Universal mouse RNA (Stratagene, La Jolla CA) was used to 
create a standard curve for each gene of interest and for the normalization gene. Gene 
reactions were run in triplicate, averaged and normalized to rat protein tyrosine 
phosphatase, receptor type C, a gene that was chosen because it showed no differential 
regulation on any of the tissue arrays. 
 
Results 
Based on our selection criteria, all of the tissues tested showed differential gene 
expression in response to a 90 min dose of  2.0% isoflurane.  Liver showed the greatest 
number of differentially regulated genes in response to isoflurane treatment with 725 of 
4900 (~15% ) genes showing either up or down differential regulation ≥ than 1.2 fold as 
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compared to the pooled control.  Kidney had fewer with 214 (~4%) differentially 
regulated genes and heart had the least with 137 (~3%). The full list of differentially 
regulated genes for each tissue is available in Supplementary Tables 1-3. 
 Of the genes described above, 34 of the 4937 genes on the arrays were 
differentially regulated in the same direction in at least 2 tissues (see Table 2 for gene 
descriptions). Of these, 19 were up-regulated and 15 were down-regulated.  Figure 2.1 
shows a Venn diagram of the distribution of the 34 co-regulated genes.  From the genes 
described in Table 2, a number of broad ontologies were represented including: 
apoptosis,  necrosis and survival signaling, regulation of energetic pathways, modulation 
of cellular redox, maintenance of cellular ion gradients, regulation of inflammatory 
response,  and regulation of vesicular transport. 
 We selected 3 of the genes that were significantly regulated on the liver arrays 
and assessed their expression levels by QRT-PCR using the same RNA as in the array 
experiments.  As shown in Figure 2.2, there was good agreement between microarray and 
QRT-PCR differential expression levels, suggesting that array values reflect a reasonable 
approximation of differential expression levels under the conditions we used.   
 
Discussion 
 Ischemic injury plays a central role in the pathology of a range of human illnesses 
from stroke and cardiac arrest to tissue transplant or complications from childbirth.  In 
the clinical setting the risk of perioperative stroke following surgical procedures present a 
small but significant risk 59.  In situations where there is a known risk of ischemic 
damage, such as during and after certain surgical procedures or organ transplant, one 
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treatment option that has shown promise for improved clinical outcomes is the use of 
delayed anesthetic preconditioning. While an intense focus on anesthetic preconditioning 
has illuminated a number of the mechanisms involved in providing protection, a complete 
picture has yet to develop.  We therefore employed a unique approach to identify novel 
genes that may be involved in common pathways of anesthetic preconditioning. In the 
current study, we used a novel approach to analyze microarray data from three rat tissues 
that prioritized genes differentially regulated in more than a single tissue. While this 
approach might prove less effective for the identification of tissue or process-specific 
pathways, it enabled us to focus on genes potentially involved in common pathways.  
Using these parameters, we identified 34 genes that were differentially regulated in 
multiple tissues following a clinical exposure to the volatile anesthetic isoflurane.  
Literature investigations of the genes contained on our list revealed a number of potential 
targets for further investigation in the context of anesthetic preconditioning. 
 Seven of the genes we identified (Vdac2, BAD, Pld1, Slc25a3, Atp1a1, MT-I, 
MT-II ) are broadly involved in apoptosis, necrosis and survival signaling.  Voltage 
dependent anion channel-2 (Vdac2) is a mitochondrial outer membrane protein.  It is a 
component of the mitochondrial permeability transition pore that participates in 
transportation of metabolites and helps regulate cellular progression towards apoptosis73.  
It is involved in the global regulation of mitochondria under stress, and has been 
implicated in the regulation of both apoptotic and necrotic pathways74, both of which are 
involved in ischemic injury. Vdac2 has also been suggested to participate in APC 31.  
Vdac2 activity is regulated, at least in part, by another in our gene list, bcl-2 associated 
death agonist (BAD) 73.  BAD has been found to be modulated during early ischemic and 
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anesthetic preconditioning 75 76, although to our knowledge, differential regulation of 
BAD has not been associated with anesthetic treatment (others have found BAD to be 
down-regulated in response to oxidative stress77).  
Phospholipase D1, is a pleotropic protein whose cleavage by caspases has been 
reported to promote apoptosis via a p53-dependent pathway 78.  Its activity during 
ischemia-reperfusion has also been tied to signaling for necrotic death 64.  Solute carrier 
family 25, member 3 (Slc25a3) is another pleotropic protein and has been reported to be a 
regulator of mitochondrial cytochrome-c release (a protein important for caspase-
dependent apoptosis) 79.  ATPase, Na+/K+ transporting alpha 1 polypeptide (Atpa1) is the 
catalytic subunit of a membrane bound Na+/K+ transporter ATPase.  The n-terminus of 
this subunit has recently been shown to interact with inositol 1, 4, 5 triphosphate receptor 
to trigger Ca2+-mediated survival signaling80,81. MT I + II have been shown to be 
protective against apoptotic and necrotic death in a number of tissues82-84. This protection 
may arise from roles in reducing oxidative stress and by triggering survival pathways that 
can protect against apoptosis and necrosis82-85. 
 Disruption of Ca2+ , Na+,  and K+ ion gradients is an important step in the 
progression of ischemia-reperfusion injury 11.  Two of the genes described above (Pld1 
and Atpa1) have described roles in the regulation of cellular Ca2+ and Na+/K+, ion 
gradients respectively 64,80.  Pld1 is a membrane protein that catalyzes the hydrolysis of 
phosphatidyl choline to for phosphatidic acid.  It has been shown to interact with protein 
kinase C (PKC) and extracellular responsive kinase (ERK) and is involved in 
sarcolemmal Ca2+ control in heart and skeletal muscle 64.  Atpa1 is an integral membrane 
protein that is involved in establishing and maintaining Na+ and K+ gradients across the 
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plasma membrane and therefore its regulation may play a role in maintaining ionic 
balance in ischemic tissue81.  
 Inflammatory response plays a significant role in later stages of ischemic injury and 
can greatly influence survival of penumbral tissue.  Four of the genes we identified, 
interferon regulatory factor 1 (Irf1), basigin (bsg) and metallothioneins I + II have been 
reported to participate in inflammatory response86,87. Irf1 regulates the transcription of the 
inflammatory cytokines interferons alpha and beta and acts as a transcriptional regulator 
of genes controlled by these proteins13.  Irf1 is also a transcription factor for iNOS, which 
has been implicated in delayed APC 40,88.  Knockout of Irf1 was recently shown to 
improve outcomes in a mouse model of ischemic stroke 86,89.  Basigin, also known as 
extracellular matrix metalloproteinase inducer (EMMPRIN), neurothelin and cluster of 
differentiation 147 (CD147), is a membrane bound protein of the immunoglobulin 
superfamily.  Through an interaction with cyclophilin A (CypA), basigin has been shown 
to be an important regulator of neutrophil infiltration in a mouse model of lung injury 90. 
Blocking the interaction of basigin and CypA lead to a 50% decreased neutrophil 
infiltration at the site of injury and reduced tissue pathology 90. Finally, MT- I + II have 
also been shown to modulate inflammatory response in rat brain.  In the rodent model of 
multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), intra-peritoneal 
administration of MT I + II was shown to reduce levels of the proinflammatory cytokines 
TNF-alpha and IL-6 91 while metallothionein knockout was associated with increased 
levels of proinflammatory cytokines IL-1, IL-3, IL-6, IL-12, TNF-alpha, lymphotoxin-
alpha, macrophage activating factor and ICAM-185.  
 In addition to its role in modulating inflammatory response, basigin has other 
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reported roles that could potentially contribute to either increased ischemic damage or to 
protection 92. In its role as an inducer of matrix metalloproteinases, it is thought to play a 
role in tissue remodeling following ischemic damage in rat heart93 and brain 94 and has 
been associated with negative outcomes. Upregulation of basigin and the associated lactic 
acid transporters MCT-1 and MCT-4 have been reported to protect against lactic acid 
damage in neuronal and cardiac tissue during ischemia 95,96.  Finally, in addition to 
regulation of neutrophil infiltration, basigin/CypA complexes have been reported to 
protect neurons from ischemic and oxidative stress 97.  Interestingly, the basigin/CypA 
interaction has been found to activate ERK1/2, p38MAPK, SAPK, and AKT:  proteins 
that are widely accepted to play a role in early preconditioning 92 31.   
Disruption of energy pathways is a core part of the pathology of ischemic injury 
11
.  Four of the co-regulated genes on our arrays (Vdac2, Prkab1, Slc25a3, and G6pc) 
have been shown to participate in the monitoring and regulation of energetic pathways. 
Vdac2, in addition to its role in apoptosis, helps to regulate the ingress and egress of 
small metabolites, including ATP and ADP from the mitochondrial space 31.  Protein 
kinase, AMP-activated protein (Prkab1) has been shown to be involved in nutrient 
sensing in conjunction with Akt and mTOR and is regulated by p53 in a stress-dependent 
manner98. Slc25a3 is a mitochondrial transport protein that is involved in the transport of 
inorganic phosphates into the mitochondrial space 99 and is therefore directly involved in 
regulating mitochondrial ATP production.  Glucose-6-phosphatase is an endoplasmic 
reticulum protein that is involved in conversion of D-glucose-6-phosphate to D-glucose 
and inorganic phosphate in liver and kidney cortex 100.   
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 In conclusion we identified a number of genes that were differentially expressed 
in rat liver kidney and heart following a clinical dose of isoflurane.  Consistent with our 
prediction, there were a number of genes that were differentially regulated in a number of 
tissues.   In order to assess functional roles for these molecules in the context of ischemic 
injury, further functional assays will have to be performed.  For our second study, we 
selected two of the genes from our list, metallothioneins I + II, for further investigation 
into their role in delayed anesthetic preconditioning. 
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Table 2.1. Primer and probe sets for QRT-PCR confirmation of selected DNA microarray data. 
 
Gene Description GenBank ID Forward Primer Reverse Primer FAM/TAMRA Probe 
Ccnd1 CyclinD1 D14014 GGGTCTGCGAGCCATGCT CCGCATGGATGGCACAAT AGACCTGCGCGCCCTCCGTTT
Prdx5 Peroxiredoxin 5 AF110732 GCTCCGTGCATCGGCTACTT ACCGCGGCACTGCTGAA AGCAGGCCGGAAAGGAGCAGGTTG
Mt2 Metallothionein 2 NM_008630 GCAAATGCACCTCCTGCAA ACACAGCCCTGGGCACATT AAAGCTGCTGCTCCTGCTGCCCC
Ptprc Protein tyrosine 
phosphatase, 
receptor type, C
M10072 ACCTACATTGGAATTGATGCCATGCT CCTCCACTTGCACCATCAGACA GAAGCAGAGGGCAAAGTGGATGTCTATGG
 
All sequences shown are 5'-3'.  Probes sequences were modified with a 5' 6-carboxy fluorescein and at the 3' end with a 6-carboxy-tetramethyl rhodamine. 
Primers and probes were designed in Primer express 1.0 (Applied Biosystems Inc, ) 
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Table 2.2. Genes differentially regulated in rat liver, kidney and heart following a clinically relevant isoflurane exposure. 
Selected genes had to be present on at least 7 of 9 arrays, found to have statistically significant (P ≤ 0.05) differential regulation 
compared to a pooled control in at least two separate tissues, and be regulated at least 1.2 either up or down in each of those tissues. 
 
Ontology Full Name Code GenBank 
accession
Potential roles in protection Liver 
Level
Kidney 
Level
Heart 
Level
Apoptotosis and necrosis, energy metabolismvol ge-dependent anion channel 2 Vdac2 AB039663 regulation of ATP consumption and regulation of apoptosis 1.53 1.23 NSR
Unknown multiple EGF-like-domains 8 Megf8 AB011534 too little data -1.25 NSR -1.36
neuronal growth and guidance ninjurin 2 Ninj2 AB040815 tissue regeneration, neurite outgrowth NSR -1.22 -1.33
DNA repair, cell cycling cyclin-dependent kinase 7 Cdk7 X83579 inhibits rnaPII, thiol center suggests role in oxidative stress -1.61 -1.38 NSR
cellular remodelling basigin (EMMPRIN/Ox47/CE-9) Bsg NM_012783 May play a role is basement membrane remodelling 2.22 1.66 NSR
energy metabolism
solute carrier family 25 (mitochondrial carrier, 
phosphate carrier), member 3 Slc25a3 M23984 involved in energy-linked phosphate transport 1.46 1.26 NSR
Neuronal growth and guidance sterol-C4-methyl oxidase-like Sc4mol D50559 axonal guidance -1.58 NSR -1.25
energy metabolism  lipoprotein lipase Lpl NM_012598
conversion to fatty acid metabolism/ ??? But regulated against what would be 
expected -1.50 NSR -1.23
Energy metabolism glucose-6-phosphatase, catalytic subunit G6pc NM_013098 energy metabolism 2.82 1.43 NSR
Secretory exocyst complex component 6 Exoc6 NM_019277 Protein secretion 1.20 NSR 1.27
Ca2+ modulation arginine vasopressin receptor 1A Avpr1a Z11690 results in increased cytoplasmic calcium in astrocytes NSR -1.29 -1.24
Vesicular trafficking
coatomer protein complex, subunit beta 2 (beta 
prime) Copb2 AF002705 intracellular vesicle trafficking -1.24 -1.20 NSR
Inflammatory response
cytochrome P450, family 4, subfamily f, 
polypeptide 1 Cyp4f1 NM_019623
role in curtailing inflammation, sexual dimorphism in expression between males and 
females 1.61 1.29 NSR
Neuronal growth and guidance
glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase Gne Y07744
encourages neurite outgrowth, sialation of sugars. . . Involved regulating growth and 
development, bind alpha actin 1.38 1.21 NSR
Cell signaling fatty acid binding protein 5, epidermal Fabp5 U13253
shown to be downregulated durig liver regeneration, fatty acid metabolism, 
regulated by retinoic acid signaling, beta catenin/notch signaling -1.74 NSR -1.27
Cell signaling Rab acceptor 1 (prenylated) Rabac1 AF025506 beta catenin signaling, role in liver regeneration 1.74 1.31 NSR
Nucleotide metabolism ureidopropionase, beta Upb1 M97662 Uracil and thymidine catabolism 1.32 1.39 NSR
Unknown tripartite motif-containing 17 Trim17 AF156272 zinc ion binding, found mostly in Testis, function largely unknown 2.21 1.53 NSR
Cell death, exocytosis, cell signalingphospholipase D1 Pld1 U69550
involved in insulin sensitivity, important for calcium regulate exocytosis, important for 
egf signaling, regulation of cell death NSR -1.20 -1.53
Protein transcription ribosomal protein L8 Rpl8 X62145 Human 60S ribosome homolog 1.55 1.25 NSR
Na, K transport and water regulationATPase, Na+/K+ transporting, alpha 1 polypeptide Atp1a1 M28647
Na, K transport, regulation of water, activity depends on redox state, with ouabain,  
catalytic subunit) bind inositol 1,4,5 triphosphate causing ca survival signal 1.66 1.25 NSR
Energy metabolism, Apoptotic pathways
protein kinase, AMP-activated, beta 1 non-catalytic 
subunit Prkab1 U42411
involved in gluconeogenesis, involved in sensing nutrient availability, regulates IGF-
1-AKT-mTOR in P53 dependent way -1.45 NSR -1.21
DNA damage response
Cas-Br-M (murine) ecotropic retroviral 
transforming sequence b Cblb AF199504 egf (epidermal growth factor) regulation, cell signaling 1.24 1.27 NSR
Transcription regulation
transcription elongation factor B (SIII), polypeptide 
2 Tceb2 L42855 increases rate of RNA polymerase transcription 1.23 1.35 NSR
DNA damage response interferon regulatory factor 1 Irf1 NM_012591 cytokine induced iNOS regulation, DNA damage reponse -1.72 NSR -1.27
Vessicle transport SV2 related protein Svop AF060173 synaptic vessicle transport, central nervous system only -1.41 -1.10 -1.24
Unknown heart endothelial unknown protein U44844 Unknown 1.63 NSR 1.25
Unknown Rat insulin-like growth factor I M81184 unknown -1.22 -1.25 NSR
Unknown proline-rich protein 15 Prp15 NM_012632 unknown 1.74 NSR 1.20
Vessicle transport synaptotagmin I Syt1 X52772
synaptotagmin, vesicular transport, ca dependent exocytosis, ca sensing forr fast 
synaptic transmission 1.62 1.31 NSR
Bilirubin catabolism
UDP glucuronosyltransferase 1 family, polypeptide 
A1 Ugt1a1 S70360 hepatic bilirubin catabolism 1.26 -1.24 -1.11
Apoptosis Bcl2-associated death agonist Bad AF279910 downregulated in cardiac, blocked by preconditioning, pro-apoptotic -1.22 -1.22 NA
Zinc Metabolism metallothionein 2 Mt2 NM_008630 Induced by MCAO and may be protective 3.77 1.41 NA
Zinc Metabolism metallothionein 1a Mt1a J00750 Induced by MCAO and may be protective 2.31 1.35 NA
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Figure 2.1.  Venn diagram of genes differentially expressed in rat liver kidney and 
heart.  Represented genes were differentially expressed on at least 7 of  9 arrays for each 
tissue, were significant (p < 0.05), and were differentially regulated in more than one 
tissue. 
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Figure 2.2.  Comparison of differential regulation of three genes by DNA 
microarray and by QRT-PCR.  The trendline represents perfect agreement between 
DNA microarray and QRT-PCR results.  The same sample of RNA was used for both 
micrarray and QRT-PCR experiments.  Microarray values shown are the average 
“median of ratios” value from 9 independent arrays ± SEM.  QRT-PCR values are the 
average  ±  SEM of 3 separate trials for each gene after being normalized to our control 
gene,  
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CHAPTER 3 
A ROLE FOR ROLE FOR METALLOTHIONEINS-I + II 
IN ISOFLURANE PRECONDITIONING OF PRIMARY MURINE NEURONAL 
CULTURES 
Introduction 
 
Given the potential for improved clinical outcomes, mechanisms of delayed 
anesthetic preconditioning have been intensely studied 60.  Since first being demonstrated 
in rabbit heart 29, preconditioning by volatile anesthetics has been described in both in 
vivo 40,101,102and in vitro 40,103 models, and in other tissues including the brain. In these 
studies, inducible nitric oxide synthase 40,102, intracellular calcium 103mitogen-activated 
protein kinase 102,103, and a variety of mitochondria related proteins19 have all been 
implicated in the cellular mechanisms of APC.  Despite these findings, a complete 
understanding of the pathways involved in APC has yet to be elucidated. 
 Recent work from our lab identified metallothionein I + II genes (MT-I + II) as 
among those significantly regulated in rat liver, kidney and heart following a 90min 2%  
isoflurane exposure104.   Furthermore, Carmel et al., 105, found MT-I + II mRNAs were 
strongly and rapidly upregulated in response to ischemic preconditioning of rat spinal 
cord. Metallothioneins-I + II are small (6000-7000 Daltons), cysteine-rich metal-binding 
proteins and have been shown to protect against a wide range of stresses including 
cardiac ischemia-reperfusion51and focal cerebral ischemia106.  To date, the relationship 
between MT-I + II proteins and anesthetic preconditioning remains to be explored.  In the 
current study, we examine protective characteristics of delayed isoflurane 
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preconditioning in dissociated neuronal culture and the role that MT-I + II play in 
conferring APC-mediated protection. 
 
Methods 
Animal Care 
C57BL/6J (C57), 129S7/SvImJ (129S, control strain for MT-I + II knockout) 
mice and 129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J (MTKO, metallothionein-I + II knockout 
strain) were purchased from Jackson Laboratories (Bar Harbor, ME) and breeding 
colonies established.  Animals were kept under a standard 12/12 light/dark cycle at room 
temperature and given access to food and water ad libitum. Animals were housed and all 
experiments carried out with protocols approved by Smith College Institutional Animal 
Care and Use Committee (Northampton, MA, USA) according to the Guide for the Care 
and Use of Laboratory Animals (National Institutes of Health, 1996). 
 
Primary neuronal cultures  
Neonatal mouse pups at postnatal day 1-3 (P1-3) were sacrificed by decapitation. 
Cortices were dissected out, minced and placed in modified DMEM (80% Dulbecco’s 
modified eagle medium; 10% fetal bovine serum, 10% F12 medium and 10 µg/ml 
Pen/Strep).  Tissue was digested in dilute Trypsin/Hanks Balanced Salt Solution (1:1) for 
25 min, quenched with 50% horse serum prior to brief centrifugation to pellet tissue 
Tissue was triturated with a fire-polished Pasteur pipette, filtered through a 
Steriflip100µM nylon filter (Millipore;  Billerica, MA) and plated onto poly-lysine 
coated wells, or in the case of immunofluorescence microscopy, on poly-lysine coated 
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glass coverslips. Cultures were maintained in an incubator (5% CO2, 95% air) at 37˚ C 
for 10-12 days in vitro. 
 
Isoflurane Preconditioning 
Isoflurane preconditioning was accomplished by placing cultures (10-12 days in 
vitro) inside a humidified exposure chamber with inlet and exhaust ports for the 
anesthetic mix.    The entire exposure chamber was housed within a 37˚ incubator.  A 
mixture of  95% air/5% carbon dioxide was passed through an Isotec 3 isoflurane 
vaporizer (GE Healthcare; Waukesha, WA) to deliver 1.5% isoflurane/93.5% air/5%CO2 
to the chamber at a rate of  0.4 l/min for 3 hrs.  Following APC, cells were washed 1X 
fresh media was added prior to replacing cells in a standard humidified carbon dioxide 
incubator.  For controls, all media changes were performed in parallel with 
preconditioned cultures.   
 
Oxygen-Glucose Deprivation 
Oxygen glucose deprivation (OGD) exposures were carried out as previously 
described40 with some modifications. Cell cultures were washed 4 times with zero-
glucose DMEM (Invitrogen, Carlsbad CA) and placed in a humidified anoxic chamber at 
37˚C.   The chamber, was evacuated and flushed 3 times with 90% N2, 5% H2, and 5% 
CO2 in order to remove oxygen.  To further reduce oxygen levels, a palladium catalyst 
was also maintained in the chamber to react any remaining oxygen with the hydrogen. 
Non-OGD samples were treated the same as OGD receiving samples, but were washed 
with standard glucose-containing culture media. 
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Quantitative reverse transcriptase-polymerase chain reaction  (QRT-PCR) of  
MT-I + II RNA levels 
Cells were harvested using a cell scraper, pooled, pelleted by centrifugation, and 
then added to Trizol reagent (Invitrogen) and stored at –20˚C for further processing. Total 
RNA for QRT-PCR analysis was isolated from Trizol/tissue homogenate using Qiagen 
Rneasy Mini kits (Qiagen: Valencia, CA).  In brief, chloroform was added to the 
Trizol/tissue homogenate and the aqueous phase was removed, mixed with 70% ethanol 
and placed on a separation column.  After repetitive washes and elution in RNAse–free 
water, RNA was quantified using a Nanodrop ND-1000 spectrophotometer (Nanodrop 
Technologies; Rockland, DE).  All samples yielded 260/280 absorbance ratios between 
1.9 and 2.1.  
QRT-PCR of MT-I and MT-II messenger RNA (mRNA) was performed using a 
mouse-modified primer/probe set (FAM/TAMRA) described by Tomita et al. 107. Primers 
and probes were synthesized by IDT inc (Coralville, IA): MTI forward 5’-
CTGCTCCACCGGCGG-3’, MT1 Reverse 5’-GCCCTGGGCACATTTGG-3’; MTI taqman 
probe: 5’-CTCCTGCAAGAAGAGCTGCTGCTCCT-3’; MTII forward 5’-
TCCTGTGCCTCCGATGGATC-3’ ; MTII reverse 5’-GTCGGAAGCCTCTTTGCAGA-3’; 
MTII taqman probe 5’-AAAGCTGCTGCTCCTGCTGCCCC-3’; LCA1 (leukocyte common 
antigen 1) forward 5’-ACCTACATTGGAATTGATGCCATGCT-3’; LCA1 reverse 5’-
CCTCCACTTGCACCATCAGACA-3’; LCA1 taqman probe 5’-
GAAGCAGAGGGCAAAGTGGATGTCTATGG-3’. All QRT-PCR reactions were carried out 
on an Applied Biosystems 7700 Taqman instrument (Applied Biosystems; Foster City, 
CA) in single tubes. The QRT-PCR reaction mix was comprised of 1X PCR buffer 
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(Invitrogen, Carlsbad, CA), 6mM MgCl2, 0.67 mM each dinucleotide, 6.75 pmols each of 
forward and reverse primers, 1.5 units Superase-in (Ambion; Austin, TX), 15 units 
Superscript II (Invitrogen), 0.75 units Platininum Taq Polymerase (Invitrogen) to a final 
volume of 15µl.  Each reaction was run one cycle of  30’ at 42˚, 1 cycle of 3’ at 95˚ and 
40 cycles of 1’ at 60˚ and 20” at 95˚. QRT-PCR for the normalization gene, mouse 
protein tyrosine phosphatase, receptor type C (PTPRC), was performed as above but 
using PTPRC primers and probe set.  Universal mouse RNA (Stratagene, La Jolla CA) 
was used to create a standard curve for each gene of interest and for the normalization 
gene, PTPRC. Gene reactions were run in triplicate, averaged and normalized to PTPRC. 
 
Lactate Dehydrogenase assay for determination of cellular toxicity 
Global cellular toxicity was assessed using the CytoTox LDH assay (Promega, 
Madison WI).   Briefly, following experimental treatment, 50µl media were removed 
from each culture well and placed in a separate well-plate.  50 µl of LDH assay solution 
was added to each well and allowed to incubate in the dark at room temperature for 30 
min.  At the end of the incubation period, 50µl stop solution was added and color change 
was measured at 490nm on a Bio-TEK µQuant UV/Vis plate reader (BioTEK 
Instruments; Winooski VT).  Net color change was determined by subtracting the average 
value of media-only wells from experimental values.  
Lactate dehydrogenase release data were first normalized using the equation 
((LDH valueIndividual well)/ (Control Average Experiment)) in order to compare results between 
different experiments.  Values for each condition were further transformed by calculating 
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average percent level of protection compared to control using the equation: (100- (100 * 
(Experimental/Control)).   
 
Microtubule associated protein-2 (MAP2)/Glia fibrillary associated protein (GFAP) 
colorimetric assays for determination of cellular toxicity 
MAP2 and GFAP colorimetric assays were performed following a modified 
protocol described by Carrier et al. 108.  Briefly, treated and control cultures were washed 
3 times in phosphate buffered saline (PBS) and then fixed at room temperature in 4% 
paraformadehyde in 0.1% sodium phosphate (pH 7.4) for 30 min.  Fixed cells were 
subsequently permeablized with 0.4% Triton-X 100 in PBS for 10 min at room 
temperature.  Cells were then washed 3 times in PBS, and blocked for 30 min in 10% 
bovine serum albumin (Sigma-Aldrich, St. Louis, MO) at room temperature.  Either 
rabbit anti-GFAP (sc-65343, Santa Cruz Biotechnology Inc, Santa Cruz, CA) or anti-
MAP2 (sc-20172; Santa Cruz Biotechnology Inc) primary antibody in 3% bovine serum 
albumin/0.4% Triton-X100 in PBS (1:100) was added to fixed cultures and allowed to 
hybridize overnight at 4˚C.  Fixed cells were then washed 3 times in 0.5% Tween/PBS 
and hybridized for 2 hrs at room temperature with horse radish peroxidase- conjugated 2˚ 
antibody at 1:2000  (sc-2004; Santa Cruz Biotechnology) in 1% bovine serum 
albumin/0.4% Triton-X 100 in PBS. Cell survival was monitored by measuring the horse 
radish peroxidase-catalyzed conversion of Amplex Red  to resorufin (Invitrogen) with 
1mM H2O2 (1mM; Sigma) in 50mM phosphate buffer. Samples from each well were 
transferred to a 96 well plate and absorbance (at 565 nm) measured on a Bio-TEK 
µQuant UV/Vis plate reader. 
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MAP2, GFAP, MT-I + II immunofluorescence microscopy for determination of MT 
localization.   
Cells for localization studies were grown on poly-lysine coated glass coverslips.  
Preparation for labeling was performed as described for colorimetric assays until the 
secondary labeling stage.  Cultures were labeled with primary antibodies for MAP2 
(rabbit anti-MAP2 polyclonal; sc-20172; Santa Cruz Biotechnology), GFAP (rabbit anti-
GFAP polyclonal; ab16997-1; AbCam) and MT-I + II (mouse anti-MT-I + II 
monoclonal; E-9; Zymed). The E9 clone has been demonstrated to be specific for MT-I + 
II and not to label other metallothioneins 109. Secondary labeling was performed using 
fluorescent dye-conjugated 2˚ antibodies (Alexa 488 goat anti-rabbit and Alexa 594 goat 
anti-mouse; Invitrogen; 1:4000) in 1% bovine serum albumin/0.4% Triton-X100 in PBS.   
Nuclei were counterstained for 3 min with 1x Hoechst (Invitrogen).  Coverslips were 
mounted on slides and visualized using an Olympus BX51 epifluorescence microscope 
(Olympus America Inc, Center Valley, PA). 
 
siRNA Knockdown of MT-I + II 
A Dicer-substrate (DsiRNA) duplex that targets both MT-I and MT-II and sham 
duplex (designed not to target any genes) were obtained from Integrated DNA 
Technologies, Inc. (Coralville, IA). RNA sequences for the metallothionein-I + II 
knockdown duplex strands were AGAACUCUUCAAACCGAUCUCUCGT and 
ACGAGAGAUCGGUUUGAAGAGUUCUAG.  Sequences for the scrambled sham duplex 
were not available from Integrated DNA technologies.  Cultures 10-12 days in vitro  were 
transfected with siRNA constructs following instructions for use of TransPass R1 
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transfection reagent (New England Biolabs, Ipswich MA).  In brief, for each well, 400µl 
of high-glucose serum-free DMEM (Invitrogen) was mixed for 20 min with 1.0 µl 
transfection solution A, 2.0 µl transfection solution B, and 20 µM duplex RNA to bring 
the final siRNA concentration to 5-10 nM. Cells were then washed 4 times with serum-
free high-glucose DMEM (Invitrogen).  Transfection mixture was added and cultures 
were returned to the incubator.  After 2 hrs, the transfection mixture was removed and 
replaced with standard media.  Cells were allowed to recover for 72 hrs prior to further 
treatment.  Transfection efficiency was assessed using immunofluorescence microscopy 
to visualize the transfection of a fluorescein-labeled siRNA control (15 nM, Fluorescein-
siRNA Transfection Control; New England Biolabs).  siRNA knockdown of MT-I + II 
was assessed by QRT-PCR under both basal and under MT-stimulating conditions (20 
µM ZnCl2, 12 hrs prior to harvest; 110, 111.  Cells were treated with sham siRNA for all 
control experiments. 
 
MT-I + II protein transfection 
Cells were transfected with either exogenous MT-I + II purified from horse liver 
(Sigma) or with a similar sized control protein (insulin oxidized ß-chain, Sigma) using 
ProteoJuice transfection reagent (Novagen, San Diego CA).  Briefly transfection reagent 
and protein were mixed 1:2 (v:w) in 25 µl of serum-free DMEM and incubated at room 
temperature for 20 min.  Meanwhile cells were washed 4 times with serum-free DMEM 
and left in serum-free DMEM.  The transfection mixture was added to each well to 
achieve a final protein concentration of 1.6-3.2 µM and cells were returned to the 
incubator at 37˚C for 2 hrs.  Transfected cells were washed 4 times in no-glucose DMEM 
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and immediately placed in an anoxic chamber for OGD treatment.  OGD toxicity was 
assessed by LDH. 
 
Statistics 
All statistics were performed in SPSS 9.0 (SPSS Inc, Chicago IL). ANOVA 
analyses were applied to data in Figures 3.1, 3.2, and 3.3 with Bonferroni post-hoc 
analyses where applicable (Figure 1).  Figure 4 required no statistics.  Figure 5 was 
analyzed by ANOVA.  Two-tailed Student’s t-tests were applied to the data in Figures 
3.1, 3.3, 3.5, 3.6 and 3. 7. Significance level was set at p < 0.05 unless stated otherwise.    
   
Results 
Isoflurane induced delayed protection against subsequent OGD-mediated toxicity in 
mouse cortical cultures.  
Isoflurane preconditioning has been shown to protect against ischemic injury in 
rat brain providing improved histologic and neurologic outcomes one month following 
preconditioning/ischemia 39 and in neuron-enriched cortical cultures 24 hrs following 
isoflurane preconditioning 40.  In order to determine if isoflurane preconditioning 
protected over an extended period in culture conditions, we evaluated OGD toxicity in 
mixed cortical cultures at 24, 48, 72 and 96 hrs post-preconditioning (Figure 3.1).  A 3hr 
pretreatment with 1.5% v/v isoflurane (a clinically relevant exposure) provided protection 
that was significant (two-tailed Student’s t-test; p < 0.01) compared to paired, non-
preconditioned controls for all time points. In detail, at 24 hrs the protection amounted to 
11.6 ± 7.9% (n=21), increasing to peak protection of  37.5 ± 2.5% at 72 hrs (n=21). The 
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effect persisted and was still robust at 96 hrs (33.4 ± 1.6%; n=32).  These data are 
consistent with isoflurane conferring delayed preconditioning via a direct 
pharmacological mechanism in dissociated primary cultures (see also Kapinya et al. 40).   
 
Isoflurane preconditioning protects neurons and glia against OGD toxicity 
To determine which cell lineages were protected against OGD by isoflurane 
preconditioning, we used an Amplex red-based immunoassay (Figure 3.2) to assess 
neuronal and glial survival following 3hrs OGD. Although 3hrs OGD was toxic to both 
neuronal and glial populations, neurons were particularly sensitive to this treatment with 
survival rates of only 39.6 ± 8.6% vs 79.0 ±  4.1 % (n=16) for glial cells.   Neurons were 
also more responsive to isoflurane preconditioning showing recovery to a 84.9 ± 4.3% 
(n=16) survival rate i.e . ~127% increase in survival.  To a lesser extent glial cells were 
also protected with a relative increase in survival rate of only ~22% (Figure 3.2). For 
neuronal populations, a 2x2 ANOVA analysis showed significant main effects of OGD 
and of isoflurane preconditioning (APC) with a significant interaction between these 
variables (p < 0.01).  This interaction indicates the effectiveness of APC in counteracting 
OGD-mediated cell death and is supported by a Student’s t-test that confirmed a 
significant (p<0.01) difference between ‘OGD alone’ and ‘APC + OGD’ conditions 
(Figure 3.2).  For glial cells, the 2x2 ANOVA analysis revealed significant main effects 
of OGD and of isoflurane preconditioning (APC) (p < 0.05) however there was no 
significant interaction between these variables (p=0.53) .  The lack of a significant 
interaction can be interpreted to mean that isoflurane preconditioning is not effective in 
protecting glia against OGD.  However, a Student’s t-test comparing the ‘OGD alone’ 
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and ‘APC + OGD’ conditions revealed a significant (p<0.01) difference between these 
groups suggesting that APC was effective but that the level of OGD toxicity was not as 
pronounced in this cell population. 
 
MT-I + II protein transfection provides protection against OGD-mediated toxicity   
Previous studies have implicated MT-I + II in neuronal protection against 
ischemia (see Carmel et al. 105, and Wakida et al. 106 ).  Kennette et al. 112 determined that 
basal levels of metallothioneins  were protective against certain toxins (e.g.  tertbutyl 
peroxide) while for other toxins (e.g. cadmium and cisplatin) MT levels had to increase 
above basal levels for protection to occur.  To discern in our system whether increased 
MT protein levels provided direct protection against OGD, we transfected cultures with 
exogenous MT-I + II protein prior to a 3 hr OGD challenge and then assessed toxicity by 
LDH (Figure 3.3).  Compared to transfection with a similarly-sized control protein 
(oxidized insulin ß-chain), MT protein transfection conferred protection  against 3hr 
OGD, rising from 2.9 ± 2.0% protection at 1.6 µM MT (not significant; n=8  ) to 
significant protection of 33.2 ± 3.1% (p < 0.001; n= 8) with 3.2 µM MT . In summary, 
these data confirm previous reports that metallothioneins are protective against ischemic 
toxicity in neuronal tissue 113. 
 
MT-I and MT-II gene expression increased following isoflurane-mediated 
preconditioning. 
Given the precedent for regulation of MT gene expression following an ischemic 
episode 12 or an anesthetic exposure 104, we examined whether MT-I and MT-II were 
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induced in mouse mixed neuronal/glial following preconditioning with a 3hr, 1.5% 
isoflurane exposure. Both MT-I and MT-II were rapidly upregulated with increases in 
mRNA levels observed as early as 3 hrs (Figure 3.4).  For both metallothioneins-I + II, 
mRNA levels peaked at ~12 hrs with levels that were 2.2 ± 0.2  and  2.8 ± 0.4 fold the 
non-preconditioned cultures for MT I and MT II, respectively.  Compared to untreated 
paired controls, MTI mRNA fold changes were significant (two-tailed Student’s t-test; p 
<  0.05) at 6 and 12 hrs and  MTII mRNA fold changes were significant at 3, 6 and 12 
hrs.  These data are consistent with those described by Carmel et al. for ischemic-
preconditioning of rat spinal cord 105 and indicates that metallothioneins are also 
regulated in response to isoflurane preconditioning.  Although it would be preferable to 
establish the timecourse of the changes in protein levels post-APC due to the small size 
and nature of the metallothioneins (e.g. highly hydrophilic, number of cysteine residues) 
we were unable to resolve metallothionein protein levels at the sensitivity required (see 
also Lu et al.) 114. 
 
siRNA knockdown of MT-I + II enhances OGD-mediated toxicity and attenuates 
isoflurane-induced protection.  
In order to assess the protective role of MT-I + II in isoflurane preconditioning, 
prior to repeating the preconditioning/OGD regimen, we transfected cultures with either a 
sham siRNA construct or an siRNA construct that targeted both MT-I and MT-II . We 
first determined the degree of MT-I and MT-II mRNA knockdown using QRT-PCR 
(Figure 3.5 A).  MT-I + II  mRNA levels were assessed under basal and under MT 
stimulating conditions (addition of 20µM ZnCl2, see Kim et al. 110). Though we were able 
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achieve only partial knockdown of either gene (Figure 3.5 A), MT-I and MT-II mRNA 
levels were diminished in a dose-dependent manner by MT-siRNA transfection. Zinc 
stimulation and siRNA knockdown both showed greater effect on MT-II than on MT-I. 
We assessed the effect of sham knockdown (ShamKD) or metallothionein 
knockdown on isoflurane-mediated protection against 3hr OGD using an LDH assay 
(Figure 3.5 B).   Isoflurane -preconditioned  ShamKD cultures  demonstrated  substantial 
protection (17.5 ± 5.2%, n=27),   similar to our findings for WT C57 cultures.    ANOVA 
analysis of the siRNA data revealed main effects of metallothionein knockdown (p < 
0.05) and of APC (p < 0.01).  However, there was no significant interaction found 
between these variables (p=0.518). This implies that the partial knockdown of the 
metallothioneins was not effective in reducing the protective influence of APC 
significantly.  However, metallothionein-I + II knockdown conditions without 
preconditioning showed substantially increased OGD-mediated toxicity compared to 
ShamKD (Figure 3.5 B). This suggests that MT-I + II below typical basal levels renders 
cells particularly vulnerable to OGD insults. Due to the incomplete knockdown of MT-I 
+ II  in the siRNA experiments, we extended our study to perform APC/OGD 
experiments with MT-I + II knockout mouse-derived cultures. 
 
MT-I + II knockout abolishes isoflurane-mediated protection against OGD toxicity.    
As a more definitive method of addressing the importance of metallothioneins to 
isoflurane preconditioning, we compared treatments on cultures prepared from MTI + II 
knockout mice (see Methods) to cultures derived from the background (129) strain 
(Figure 3.6). Similar to our previous experiments with C57 mice (Figure 3.1), 
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preconditioned background  (129)-derived cultures showed significant protection (two-
tailed Student’s t-test; p < 0.001) against OGD toxicity (26.2 ± 3.6%; n=16) as compared 
to paired non-preconditioned samples.  By contrast knockout-derived cultures (MTKO) 
showed no protection from isoflurane preconditioning (1.5% ± 3.7%; n=25, Figure 3.6 
B). Both 129 WT and MTKO cultures were assessed by LDH for toxicity from isoflurane 
preconditioning alone. Preconditioned 129 WT cultures showed LDH levels of 97 ± 11% 
of untreated cultures and MTKO cultures showed LDH levels 124% ± 19% their 
untreated counterparts at 48 hrs post-isoflurane exposure (n=16).  There was no 
significant difference between treated and untreated cultures in either 129 WT or MTKO 
cultures (two-tailed Student’s t-test, p = 0.86 and p =0.49 respectively).  These data 
provide compelling evidence of a critical role for metallothioneins in isoflurane–mediated 
preconditioning.     
 
Metallothionein-I + II proteins are primarily localized to neuronal cytoplasm in 
mouse neonatal cortical cultures. 
In light of our finding that APC provided more protection from OGD to neurons 
rather than glia, we determined the cellular localization of MT-I + II proteins (Figure 
3.7). Previous studies in mouse brain have shown metallothioneins-I + II to be localized 
primarily in glial cells 115,116, 106.  Here we used immunofluorescence microscopy to 
assess the colocalization of a monoclonal MTI + II antibody with either neuron-specific 
MAP2 antibodies or glial-specific GFAP antibodies.  In C57- and 129-derived cells the 
metallothionein antibody colocalized strongly with MAP2 labeled cell bodies indicating 
strong neuronal localization (Figure 3.7 A). GFAP-labeled cells showed metallothionein 
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co-localization to a lesser extent (data not shown). Neither MT knockout-derived cultures 
nor 129 wild type (WT)  cultures coincubated with 10 µM horse MT-I + II protein 
demonstrated measurable MT labeling, consistent with MT-I + II specific labeling 
(Figure 3.7 B and C).  
 
Discussion 
Delayed anesthetic preconditioning has been shown to be a powerful tool for 
improving both histological and clinical outcomes against ischemia-mediated toxicity in a 
number of tissues 101, 117.  Given the relative safety of preconditioning with anesthetics vs 
surgically-induced ischemia 59, there is emerging interest in anesthetic preconditioning.  
In this study, we used a dissociated cortical neuronal culture model to investigate the 
direct pharmacological effects of isoflurane preconditioning and the role that MT-I + II 
play in mediating that protection. An in vitro dissociated tissue culture model of neuronal 
APC/OGD presents a number of advantages over in vivo models including the ability to 
measure direct pharmacological effects of the anesthetic agent while avoiding the 
confounding influences of hemodynamics, cardiac depression and other anesthesia 
mediated physiological factors. An in vitro model also provides more flexibility for 
manipulation and direct observation of outcomes in studying molecular mechanisms.   
Inevitably, however, a dissociated culture model has limitations.  For instance, the in 
vitro OGD model cannot be used to assess system-wide effects of ischemic injury such as 
inflammatory and immune response to injury.  Furthermore focal ischemia models enable 
observations of long-term outcomes in vivo. Despite these constraints, we have shown 
that dissociated culture with OGD is a useful model for studying APC and OGD, and that 
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the time course of protection mirrors that of in vivo models 40, 117.  In future, it will be 
necessary to follow up our experiments with studies on the role of metallothioneins 
during anesthetic preconditioning in vivo.   Moreover, as MTs can be induced through 
various conditions 85, this work may have important implications for improved clinical 
outcomes. 
The principle findings of our study are as follows:  1). Pretreatment with 1.5% 
isoflurane provided robust protection against OGD toxicity that peaked 72 hrs following 
isoflurane exposure.  2). OGD was more toxic to neurons than to glia although 
preconditioning with isoflurane significantly reduced toxicity in both populations. 3.) 
Exogenous MT protein supplementation was directly protective against OGD toxicity. 4). 
MT-I + II mRNAs were rapidly and robustly induced by treatment with clinically-
relevant doses of isoflurane.    5.)  siRNA knockdown of MT-I + II diminished isoflurane 
diminished protection against an OGD insult.  6). MT-I + II gene knockout abolished 
isoflurane mediated protection and rendered cultures more susceptible to OGD than WT 
cultures  7.) MT-I + II localized to neuronal cell bodies, although were also seen in glial 
cytoplasm.  Combined these data argue for an important role of metallothioneins-I + II in 
isoflurane-mediated protection against OGD.  To our knowledge, this is the first time 
metallothioneins-I + II have been revealed as important mediators of isoflurane 
preconditioning.   
 There are several reports supporting a protective role of MT-I + II in a number of 
tissues.  In particular, MT-I + II have been implicated in protection against ischemic 
injury in brain 106, 118, heart 51,119  and kidney 120. Campagne et al. 118found MT 
overexpressing mice not only had better histologic outcomes, but also significantly 
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improved motor performance 3 weeks following focal cerebral ischemia/reperfusion. 
Wakida et al. 106 found erythropoietin-induced MT-I + II reduced infarct area and volume 
at 24 hrs following permanent middle carotid artery occlusion (MCAO) damage in rat 
brain. Of direct relevance to our study, Carmel et al. 105 found MT-I + II mRNAs were 
rapidly induced in rat spinal cord following brief ischemic preconditioning. Together 
these data complement our findings that MT-I + II are rapidly induced following 
isoflurane preconditioning and that the increased MT levels provide protection against 
subsequent ischemic injury. 
 A surprising result was the localization of MT-I + II to neuronal cell bodies along 
with weaker glial staining (Figure 3.7).  While this localization correlates well with the 
robust APC-mediated neuronal protection (Figure 3.2), it contrasts with previous reports 
that metallothioneins-I + II localize primarily within glia in the brain with little to no 
expression in neurons 115.  These localization differences may be accounted for by a 
number of experimental variations including developmental stage of our cells, differences 
in structure of cells grown in culture vs in vivo, or differences in fixing procedures (see 
Hidalgo et al., 2001115).  Neuronal localization may be accounted for by recent work by 
Chung et al. 121, who found MT-I + II can be exported by astrocytes and readily taken up 
and utilized by neurons.    
While our study demonstrated that MT-I + II can be protective against OGD, the 
mechanism by which MT-I + II confer this protection remains to be determined.  
Metallothioneins are small (~6000-7000 Da) metal-binding (primarily Zn2+and Cu2+) 
proteins that are expressed throughout the body.  They exhibit a number of cellular 
activities that could potentially account for their protective role against ischemia (see 
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Penkowa, 85). These roles include modulation of cellular redox, immune defense 
response, mitochondrial respiration, angiogenesis, cell-cycle progression, cell survival 
and differentiation. An intriguing role for MTs in preconditioning is as a critical 
component of the nitric oxide signaling cascade 122 that has been identified as essential 
for induction of delayed isoflurane-induced preconditioning in heart. 117. Stitt et al., 123 
studying nitric oxide signaling in mouse lung endothelial cells, showed that 
metallothionein was essential for nitric oxide-mediated translocation of the transcription 
factor MTF-1 (metal-responsive transcription factor 1) to the nucleus and for subsequent 
upregulation of metallothionein.  These data support a role for metallothioneins in nitric 
oxide signaling during ischemic stress. 
In addition to possibly participating in nitric oxide signaling, another potential 
role for MT’s in APC-mediated protection is as an end effector of cellular protection.  
This is supported by the findings, shown in Figure 3.3, in which transfection of 
exogenous MT-I + II protein provided immediate protection against OGD damage.  As an 
end effector, MTs might act as antioxidants to detoxify reactive oxygen species produced 
by the energy pathway imbalances of ischemia (see Penkowa 85).  In support of this, 
increased MT levels have been shown to decrease both reactive oxygen species levels 
and peroxidation of cellular proteins and lipids 124. Furthermore the antioxidant effects of 
MTs during mitochondria-specific oxidative stress have been shown to result in greater 
protection than provided by Cu/Zn-SOD, glutathione peroxidase, Mn-SOD or catalase 53.  
Alternatively, MT-mediated protection may depend on the central role metallothioneins 
play in zinc homeostasis85.  Approximately 3% of the mammalian proteome requires zinc 
for some aspect of functionality with 40% of zinc binding proteins acting as transcription 
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factors and the remaining 60% proteins involved in ion transport or as enzymes 125. 
Through their role in zinc homeostasis,  MTs may have pleiotropic effects in ischemic 
tissue which affect a range of responses from transcription to ion homeostasis through 
modulation of zinc availability throughout the cell.  
In conclusion, this study describes an important role for metallothioneins-I + II in 
isoflurane preconditioning against OGD.  Based on the role that MT’s play in isoflurane-
mediated delayed protection against OGD, our results implicate metallothioneins-I + II as 
possible molecular targets for improving clinical outcomes during ischemic injury.  
Further studies to clarify the mechanisms of metallothionein I + II action will be essential 
for understanding metallothionein-mediated protection and their potential for protection 
against ischemic injury.   In the final study of the dissertation, we address a possible role 
for metallothioneins in delayed anesthetic preconditioning as sensors in an oxidative 
stress signaling pathway. 
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Figure 3.1.  Isoflurane induces delayed protection against oxygen glucose 
deprivation in murine mixed  neuronal and glial cultures. Lactate dehydrogenase 
release (LDH) was used to assess oxygen-glucose deprivation (OGD)-mediated toxicity 
in both untreated and isoflurane preconditioned (1.5% isoflurane; 3 hrs) cultures at 24, 
48, 72 and 96 hours post preconditioning.  Percent protection (mean ± SEM) was 
calculated using the equation: 100-(100 x (Mean Test LDH/Mean Control LDH)).   Protection is 
reported as compared to days in vitro- matched controls. *Significance: (p<0.01, two-
tailed Student’s t-test). Inset indicates timecourse for experimental procedure.  
**Significant difference between timepoints and ‘NS’ denotes No significant difference 
for an ANOVA with Bonferroni post-hoc analysis (p<0.05). 
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Figure 3.2.  Neurons and glia are protected by isoflurane preconditioning.  Mouse 
cortical cell culture subpopulations were assessed for oxygen-glucose deprivation 
(OGD)-induced toxicity and isoflurane-induced protection by immunolabeling for 
neurons with horse radish peroxidase-conjugated antibodies to microtuble associated 
protein -2 (MAP2) and for glia with glial fibrillary associated protein GFAP.  
 *Significance: (p<0.01, n=16, two-tailed Student’s t-test).  Inset indicates timecourse for 
experimental procedure.  
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Figure 3.3.  Transfection with exogenous metallothionein-I + II protein protects 
primary cortical cultures against oxygen glucose deprivation -mediated toxicity.   
Primary cortical cultures were transfected with 1.6µM or 3.2 µM metallothionein-I + II 
(MT-I + II) protein or 3.2 µM oxidized insulin ß-chain (control).  Toxicity was assessed 
by lactate dehydrogenase release assay.   *Significance:  (p<0.001, two-tailed Student’s t-
test). Inset indicates time course for experimental procedure. 
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Figure 3.4.  Metallothionein I and II mRNA levels are increased following isoflurane 
preconditioning. Primary cortical cultures were preconditioned with 1.5% isoflurane for 
3hrs.  Cells were collected at 5 time points (T=0, 3, 6, 12, and 24 hrs) post-exposure, and 
metallothionein-I (MT1) and metallothionein-II (MTII) mRNA levels were assessed by 
quantitative reverse trancriptase-polymerase chain reaction (QRT-PCR), normalized to 
protein tyrosine phosphatase, receptor type C (PTPRC) expression.   *Significance: ( p < 
0.05; n=5;  two-tailed Student’s t-test).  
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Figure 3.5.  Metallothionein short interfering RNA reduces Metallothioneins I and 
II mRNA levels in a dose-dependent manner and  increases vulnerability to oxygen 
glucose deprivation. (A) Quantitative reverse transcriptase-polymerase chain reaction 
(QRT-PCR) was used to assess metallothionein I + II knockdown by a short interfering 
RNA (siRNA) against metallothioneins-I + II (MTKD).  A sham siRNA (ShamKD) 
construct was used as the control.  ZnCl2 was used to simulate metallothionein-
stimulating conditions.  (B) OGD-mediated toxicity was assessed by lactate 
dehydrogenase release assay in mixed cortical cultures transfected with either ShamKD 
or the MTKD siRNA constructs.   See Results for discussion of significance (n=27).  
Insets indicate time course for experimental procedure.  
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Figure 3.6. Knockout of metallothionein-I + II genes abolishes isoflurane-mediated 
protection against  oxygen-glucose deprivation.    Oxygen glucose deprivation (OGD)-
mediated toxicity was evaluated following 3hr, 1.5% isoflurane preconditioning in mixed 
neuronal/glial cultures from A.) Background strain (129) and B.) Metallothionein-I + II 
(MT-I + II) knockout mice (MTKO).  *Significance: p<0.001, two-tailed Student’s t-test. 
Inset indicates time course for experimental procedure. 
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Figure 3.7.  Metallothioneins-I + II localize to neuronal cell bodies  cortical neuronal 
cultures. Metallothionein-I + II (MT-I + II) localization was visualized by epifluoresence 
microscopy. Cultures, 10 days in vitro, were labeled using a monoclonal antibody against 
MT-I + II and a polyclonal antibody against microtube associated protein-2 (MAP2). 
Secondary labeling was accomplished with alexafluor 488 or alexafluor 594 fluorescent 
conjugates. A.) 129 cells, nuclei were stained with Hoechst.  B.)  MT-I + II knockout 
cells.  C.) 129 cultures, antibody pre-incubated with 10 µM horse MT-I + II protein to 
show MT antibody specificity.   
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CHAPTER 4 
A ROLE FOR METALLOTHIONEINS I + II AS SENSORS OF 
OXIDATIVE STRESS IN ISOFLURANE-MEDIATED DELAYED 
ANESTHETIC PRECONDITIONING. 
Introduction 
 
  Ischemic injury progresses via a complex cascade of events that includes 
diverse, but intertwined ontological pathways 11.  Recent studies have identified a range 
of molecules that are involved in delayed anesthetic preconditioning including COX-2 48, 
NF-Kappa B 41, PI3 kinase 55, K(ATP) channels 58, Mn-SOD 61, and 12-lipoxygenase 54.  
In addition to the above molecules, the reactive oxygen species, superoxide and the 
reactive nitrogen species, nitric oxide have received particular attention for their essential 
role in inducing delayed anesthetic preconditioning47,50,126.  Despite significant evidence 
implicating ROS and RNS in the induction of delayed APC, how they exert a protective 
effect is not well understood.   
Superoxide-mediated oxidation of cysteines on the zinc binding proteins 
metallothioneins I + II has been shown to result in the release of zinc to the cell 
cytoplasm127.  Recent studies in mouse lung endothelial cells have demonstrated that 
metallothioneins I + II are also important targets of nitric oxide, again resulting in release 
of bound zinc 123,128-130.  Furthermore, it has been shown that pharmacological nitric 
oxide donors are able to induce sufficient zinc release from metallothioneins to activate 
metal-responsive transcription factor-1 (MTF-1), the primary transcription factor 
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regulating metallothionein expression during oxidative and heavy metal stress131.  
Activation of MTF-1 by increased cellular zinc causes it to translocate from the 
cytoplasm to the nucleus leading to increased metallothionein production123. It has been 
hypothesized that MTF-1, in conjunction with oxidative release of zinc from 
metallothioneins, may participate in a novel signal transduction pathway that provides 
protection against oxidative stress 131-134. Given that ROS and RNS are widely reported to 
play instrumental roles in the induction of delayed preconditioning, combined with our 
recent finding that metallothioneins I + II play a central role in delayed preconditioning 
45
, we, in this final study, investigated a possible role for metallothioneins as sensors of 
oxidative stress following preconditioning with the inhaled anesthetic isoflurane, the 
reactive nitrogen species nitric oxide and the oxygen radical superoxide.  
 
METHODS 
 
Animal Care 
129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri/J (MTKO, metallothionein-I + II knockout) 
and 129S7/SvImJ (129, control strain for MT-I + II knockout) mice were initially 
purchased from Jackson Laboratories (Bar Harbor, ME) and a breeding colony 
established.  Animals were kept under a standard 12:12 light:dark cycle at room 
temperature and given access to food and water ad libitum.  Animals were housed and all 
experiments carried out with protocols approved by Smith College Institutional Animal 
Care  and Use Committee (Northampton, MA, USA) according to the Guide for the Care 
and Use of Laboratory Animals (National Institutes of Health, 1996). 
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Primary neuronal cultures  
Neonatal mouse pups postnatal day 1-3 (P1-3) were sacrificed by decapitation. 
Cortices were dissected out, minced and placed in modified DMEM (80% DMEM , 10% 
FBS, 10% F12 medium and 10 µg/ml Pen/Strep).  Tissue was digested in dilute 
Trypsin/HBSS (1:1, v/v) for 25 min, then quenched with 50% horse serum prior 3min 
centrifugation to pellet tissue.  The tissue was triturated then filtered through a Steriflip™ 
100µM nylon filter (Millipore; Billerica, MA) and plated onto poly-lysine coated tissue 
culture plates.  Cultures were maintained in a 5% CO2 incubator at 37˚C  for 10-12 days 
in vitro (DIV 10-12). 
 
 
Preconditioning Regimens 
Isoflurane preconditioning was accomplished using a humidified exposure 
chamber containing inlet and outlet ports housed inside a 37˚ incubator. Cultures (DIV 
10-12) were placed in the exposure chamber and an air/CO2 mix (95% air/5% CO2) was 
passed through an Isotec 3™isoflurane vaporizer (GE Healthcare; Waukesha, WA) to 
deliver 2.5% isoflurane/ 92.5% air/ 5% CO2 at a rate of  0.4 L/min for 2 hrs.  In 
experiments blocking iNOS and superoxide, cells were incubated with the inducible nitric 
oxide synthase inhibitor, aminoguanidine (AG, 1.0 mM, Sigma) and the superoxide 
dismutase mimetic manganese (III) tetrakis (4-benzoic acid) porphyrin chloride 
(MnTBAP, 1.0 M, Sigma), respectively, 2 hrs prior to the anesthetic preconditioning.   
Freshly made S-Nitroso-N-acetylpenicillamine (SNAP, 200µM, Sigma), degraded 
SNAP (SNAP degraded at 37˚ overnight in culture media), and paraquat (5µM, Sigma) 
were used for nitric oxide and superoxide preconditioning respectively.  Cultures were 
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returned to the incubator for the 2 hr preconditioning period.  All preconditioning 
regimens were followed by 3 washes with fresh media.  Cultures used for toxicity assays, 
were returned to the incubator for 72 hrs until OGD (see below) in order to achieve peak 
isoflurane mediated-protection, 45.  Cultures being used for MTF-1 translocation 
experiments were processed immediately for nuclear protein extraction 123.   Each media 
change performed in preconditioned cultures was performed in parallel in control 
cultures. 
 
Oxygen-Glucose Deprivation 
Oxygen glucose deprivation (OGD) exposures were carried out as previously 
described 40,45 with some modifications. Cell cultures were washed 4 times with zero-
glucose DMEM (Gibco) and placed in a humidified anoxic chamber (model A-141, 
Sheldon Mfg., Cornelius, OR) at 37˚C.   The chamber was evacuated and flushed 3 times 
with 90% N2, 5% H2, and 5% CO2. A palladium catalyst was maintained in the incubator 
to further diminish O2 levels.   Cultures were maintained in the anoxic chamber for 4 hrs 
prior to LDH assay.  All control cultures not receiving OGD treatment were handled in 
parallel, but washes were performed with standard media rather than with OGD media. 
 
Lactate Dehydrogenase assay for determination of cellular toxicity 
Global cellular toxicity was assessed using a CytoTox™ LDH assay (Promega, 
Madison WI).   Briefly, following experimental treatment, 50µl media were removed 
from each culture well and placed in a separate well-plate.  50 µl of LDH assay solution 
was added to each well and allowed to incubate in the dark at RT for 30 min.  At the end 
of the incubation period, 50µl stop solution was added and color change was measured at 
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490nm on a Bio-TEK µQuant™ UV/Vis plate reader (BioTEK Instruments; Winooski 
VT).  Net color change was determined by subtracting the average value of media-only 
wells from experimental values.  In order to compare results between experiments, data 
were normalized to “% normalized protection” by dividing each individual experimental 
value by the average control value.  Thus the equation for generating normalized data 
was as follows: 100-100*( AbsExperimental -AbsAverage-edia) / AbsAverage(-contro)l-AbsAverage-Media) 
%.  
 
Isolation of nuclear proteins for determination of MTF-1 translocation 
Immediately following preconditioning regimen, plates were washed 3X with ice 
cold PBS.  Cells were then scraped with 1mL PBS on ice, placed in a microcentrifuge 
tube and spun at 500 x g for 3 min to pellet the cells.  The supernatant was then removed 
and replaced with the outer membrane lysis buffer (0.01M Hepes, 1.5mM MgCl2, 0.01M 
KCl, 1.0mM, DTT ) at ~10X packed cell volume  and incubated on ice for 15 min. 
Igepal-CA630 non-ionic detergent (10% v/v; Sigma) was added to the cell suspension for 
a final concentration of 1%.  Samples were immediately vortexed and centrifuged at 
21000 x g for 5 min.  Supernatant containing cytosolic proteins was removed and the 
pellet containing nuclei was washed 2x in 500µL Buffer I (without Igepal).  The nuclear 
pellet was then resuspended in 200µl Buffer II (nuclear extraction buffer; 0.02M HEPES, 
1.5mM MgCl2, 0.42 M NaCl, 200µM EDTA, 25% glycerol, 1.0mM, DTT), pipette-
mixed to break up pellet, and incubated on ice for 40 min.  Samples were then vortexed 
for 30 secs and centrifuged at 21000 x g for 15 min.  Supernatant containing the nuclear 
fraction was transferred to a fresh tube.  Protein concentration was determined by BCA 
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assay (Pierce), and samples were stored at -20 C.  The nuclear pellet was observed prior 
to nuclear lysis by phase-contrast and epifluorescence microscopy (with Hoeschst 33342 
nuclear stain; Invitrogen) and found to contain only nuclei with little to no cellular debris 
(not shown). 
 
Western Determination of MTF-1 levels 
Nuclear proteins (20µg) were separated by electrophoresis on 4-12% Bis-Tris 
polyacrylamide gels (Novex, Invitrogen) and transferred to 0.45µM nitrocellulose 
membrane (Invitrogen).  Membranes were probed with a polyclonal antibody against 
MTF-1 (1:750; Santa Cruz Bio, SC-48775) and detected with an HRP-conjugated anti-
rabbit 2˚ antibody (1:100,000 Santa Cruz Bio, SC-2004).  Bands were visualized with 
Supersignal West Pico chemiluminescent Substrate (Pierce) and detected on film (Kodak 
X-Omat LS, Sigma).  Relative densitometry was performed in Photoshop 9.02 (Abobe 
Inc., San Jose, CA) for quantitative analysis of bands from 3 replicates of each 
condition135. 
 
Statistics 
All statistics were performed in SPSS 9.0 (SPSS Inc., Chicago IL).  Normalized 
toxicity/protection data were analyzed by ANOVA (Figures 4.1 A and 4.2 A and 4.3 A).  
Significance level was p < 0.05 unless otherwise stated. 
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Results 
Nitric oxide and superoxide generators precondition wild type cultures and promote 
nuclear translocation of MTF-1. 
Growing evidence supports the role of reactive oxygen and reactive nitrogen 
species as the primary initiators of preconditioning 47.  In this group of experiments, we 
attempted to use the nitric oxide donor SNAP, a degraded form of SNAP, and the 
superoxide generator paraquat as preconditioning agents.   Similar to previously 
described preconditioning experiments using isoflurane as the preconditioning agent40,45, 
SNAP preconditioned cultures demonstrated significant protection against OGD (37.6 ± 
3.4%; n=28) compared to non-preconditioned cells in WT cultures (p < 0.001; n=28) 
(Figure 4.1 A). Cells treated with the same concentration of SNAP that had been heat 
degraded (37˚, 24hrs) were not significantly protected  8.3 ± 6.7 % (p = 0.4; n=14) and 
were significantly less protected than the SNAP preconditioned cultures (p < 0.01; n=14). 
Paraquat preconditioned cultures showed significant protection (24.2 ± 3.6%; n=14; p < 
0.01) compared to untreated controls.  In order to ensure that outcomes were the result of 
preconditioning only, cultures were assessed for treatment-mediated toxicity by taking 
media just prior to OGD treatment.  SNAP, decomposed SNAP and paraquat showed 
only small differences from basal control LDH levels (75.2 ±  2.6%, p= 0.18, n= 6), (65.5 
± 1.1%; p < 0.05; n=6) and (82 ± 3.1%;  p= 0.26, n=6) of control levels respectively.; p = 
0.18 and p < 0.05 respectively; n=6) . Though the degraded SNAP value was statistically 
significant, it represented a small absolute difference from the control value and were not 
considered to affect the final outcome 
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Reactive oxygen and nitrogen species have previously been shown to induce 
nuclear translocation of MTF-1 133.  We were interested to determine if the 
preconditioning described above correlated with increased nuclear MTF-1 localization.   
Following 2hrs on from the initiation of preconditioning, SNAP and paraquat treatments 
resulted in increased nuclear MTF-1 levels (by 72 ± 21%  and 231 ± 103% above 
untreated control levels respectively; n=3, Figures 4.1 B and C).  Degraded SNAP 
showed minimal MTF-1 translocation compared to non-degraded SNAP (17 ± 4.9% 
above untreated control; n=3, Figures 4.1 B and C).   Together these results support a role 
for MTF-1 in NO and .O2 –induced delayed protection. 
 
Isoflurane preconditions wild type cultures and promotes nuclear translocation of 
MTF-1 
Given the above finding that nitric oxide and superoxide generators were able to 
induce delayed preconditioning and that the protection corresponded with increased 
nuclear MTF-1 localization, we determined whether a clinically relevant dose of 
isoflurane would yield similar results.  In agreement with earlier reports40,45, 
preconditioning with a 2 hr, 2.5% isoflurane exposure provided significant levels of 
protection against 4hr oxygen-glucose deprivation (29.8 ± 2.2% ; p < 0.001; n=15) 
compared to non-preconditioned cultures (Figure 4.2 A). Also in agreement with 
previous results17,40, the inducible nitric oxide inhibitor, aminoguanidine and the 
superoxide dismutase mimetic, MnTBAP, diminished isoflurane-mediated protection to 
5.8 ± 4.9 % (p = 0.47; n=18) and 6.8 ± 4.8% (p = 0.28; n=14) of control levels.  Similar 
to findings with pharmacologic nitric oxide and superoxide donors, Western blot analysis 
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showed isoflurane treatment corresponded with increased nuclear localization of MTF-1 
(55 ± 2.4% above untreated controls; n=3).  Pretreatment with aminoguanidine and 
MnTBAP reduced these nuclear MTF-1 levels to -6.0 ± 7.3% (n=3) and 20 ± 2.9% (n=3) 
above control levels respectively (Figures 4.2 B and C).  These data support a role for 
MTF-1 in NO and .O2 –induced delayed protection as a result of isoflurane exposure 
 
Knockout of MT-I + II diminishes isoflurane, nitric oxide, and superoxide-mediated 
preconditioning and diminishes nuclear MTF-1 levels. 
Metallothioneins I + II have been shown to play a central role in RNS/ROS 
mediated translocation of MTF-1123 and we recently showed that they are important for 
the induction of isoflurane-mediated delayed preconditioning 45.  In these experiments, 
we wanted to determine if the loss of MT-I + II genes would affect preconditioning by 
SNAP and paraquat and if this would correlate with nuclear MTF-1 translocation. In 
agreement with previous isoflurane preconditioning data 45, isoflurane, nitric oxide and 
paraquat provided no significant protection against 4hr OGD compared to untreated 
controls in metallothionein I + II knockout-derived cultures (0.92 ± 1.8%; n= 22; p = 
0.81),  (-1.58 ± 2.7%; n=24, p = 0.76), and (-5.6 ± 4.1%; n=14, p = 0.24) respectively 
(Figure 4.3).  Toxicity of the treatments alone in knockout-derived cultures was assessed 
by LDH following the 72 hr preconditioning window there was no significant toxicity 
from any of the treatments alone (paraquat 8 ± 4.2% above control levels ; n=8; p=0.21),  
anesthetic preconditioning (12 ± 8.5% above control levels; n=8; p=0.27) and SNAP (2.0 
± 3.7% below control levels; n=8; p= 0.57; n=8)  
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Western analysis of nuclear MTF-1 levels in metallothionein knockout cultures 
showed that nuclear MTF-1 levels were increased 3.0 ± 9.7%, 18 ± 3.0%, and 31 ± 2.7% 
respectively, above controls (n=3 for each).  Though preconditioning appeared to 
increase nuclear MTF-1 localization, levels were sharply attenuated compared to wild 
type cultures (Figure 4.3 B and C).  Taken together, these data support an important role 
for metallothioneins I + II both in propagating NO signaling, but also in NO and .O2 
mediated protective signaling. 
 
 
Discussion 
Protection through delayed preconditioning has been demonstrated in variety of 
tissues40-43,45,136 and animal models38,40,45,46,136 resulting in  improved histological and 
functional outcomes.  Furthermore, the relative safety of anesthetic preconditioning 
compared to ischemic preconditioning6 59, and the global nature of its protection has 
contributed to growing interest in the mechanisms of APC.  While many aspects of the 
delayed preconditioning mechanism have been described, there are still gaps in our 
understanding.  Reactive nitrogen species, primarily in the form of nitric oxide 
40,42,47,50,117and reactive oxygen species such as superoxide 49,137have been shown to be 
important mediators of delayed preconditioning. However, the mechanism by which 
these molecules are able to confer protection is not well understood. We recently reported 
that the metal-binding proteins metallothioneins I and II are important for isoflurane-
mediated delayed preconditioning 45.  In the current study, we used a dissociated neuronal 
culture model to examine the hypothesis that metallothioneins I + II play a role in RNS 
and ROS signaling and protection during delayed anesthetic preconditioning. Using an in 
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vitro model allowed us to isolate direct pharmacologic effects of the preconditioning 
agents while avoiding confounding variables such as changes in hemodynamics, cardiac 
depression, and other anesthetic related physiological effects.  Nevertheless, an in vitro 
model has limitations.  For example, it is not well suited to address system effects such as 
inflammation, immune response, and drug clearance that may play an important role in 
long-term outcomes of ischemic injury 11.  Furthermore, in vivo models are better able to 
evaluate long-term cognitive and neurological outcomes of protection and ischemia.  
Despite these constraints, in vitro models have been shown by us and others to be useful 
models for studying the acute effects of anesthetic preconditioning, with similar time 
courses and levels of protection to in vivo models 40,45,103,138. 
In this study, we determined the following:  1.) As previously reported40,45, 
isoflurane preconditioning provided significant cellular protection against 4hr OGD while 
the nitric oxide synthase inhibitor aminoguanidine and the superoxide scavenger  
MnTBAP diminished the protective effects of isoflurane preconditioning.   2.)  Isoflurane 
treatment corresponded to increased nuclear localization of metal-reponsive transcription 
factor-1 in wild type cultures.  Pretreatment of cells with aminoguanidine or MnTBAP 
diminished the effects of isoflurane preconditioning on MTF-1 nuclear localization.  3.) 
Preconditioning with the nitric oxide generator, SNAP, (but not the oxidized version of 
the molecule) or the superoxide generator, paraquat, was able to protect WT-derived 
cultures against 4hr OGD with time courses and magnitudes of protection similar to 
isoflurane preconditioning.  4.)  As in isoflurane preconditioning, treatment of wild type 
cultures with SNAP or paraquat induced nuclear translocation of MTF-1.  5.)  Knockout 
of metallothionein I + II genes abrogated the protective effects of all of the 
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preconditioning agents.  5.)  Isoflurane, SNAP and paraquat treated knockout cultures 
showed increased MTF-1 levels, though to a lesser extent than those seen in wild type 
cultures.  These data support an essential role for metallothioneins I + II both transducing 
ROS and RNS signaling and protection.  While we expected MTF-1 localization to drop 
to control levels or below in MT knockout experiments, the discrepancy may be due to 
the presence of another isoform of metallothionein, MT-III, a form found primarily in the 
brain139,140.  Though this molecule is typically attributed different functions from those of 
MT I + II 141, its structural similarities might contribute to the regulation of MT-I + II 
synthesis through MTF-1 modulation. 
In combination with a number of studies on the mechanisms of nitric oxide 
signaling123,128,129,131,133, our data support a role for metallothioneins I + II as sensors of  
increased nitric oxide and superoxide during delayed isoflurane-mediated protection.  In 
Figure 4.4, we present a possible model for this pathway. The pathway begins with the 
generation of nitric oxide by iNOS 40,50,142 eNOS 52,143, or a combination of the two 
following the administration of the preconditioning agent.  In the presence of superoxide, 
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 nitric oxide will react to form peroxynitrite 11.  Nitric oxide alone  122,128,144, superoxide 
alone 127,145 and peroxynitrite 146 have each  been shown to react with the cysteines that 
make up a third of the ~60 amino acids that make up metallothioneins I + II.  This 
reaction triggers a confirmational change in metallothionein that results in the release of 
zinc from one or both its two zinc-binding domains 146,147.   Zinc then complexes with 
cytoplasmically localized MTF-1, causing the metal response element-binding 
transcription factor to translocate to the nucleus123,148.  This translocation may rely on a 
cytoplasmic interaction with hypoxia-inducible transcription factor-1 149.   Once in the 
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nucleus, MTF-1 binds the metal response element, inducing the production of apo-
metallothionein I + II (aka, thionein) 85,45.  Apo-metallothionein and the zinc-bound 
metallothionein then have a broad range of described activities that potentially play a role 
in preconditioning-mediated protection including buffering cellular zinc concentrations 
150
, buffering cellular redox 151, acting extracellularly to activate cellular survival 
pathways 121,152, suppressing local inflammatory response 91, modulating mitochondrial 
respiration 153, modulating enzyme activity through zinc modulation 154,and protecting 
mitochondria against oxidative damage 85. 
 This study presents evidence of an important role for metallothioneins I + II as 
sensors of oxidative stress in anesthetic-mediated delayed preconditioning.  Further 
studies will be important to unravel  the mechanisms by which metallothioneins are able 
to contribute to protection against toxic ischemia.   
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Figure 4.1.  The nitric donor SNAP and the superoxide generator paraquat 
precondition wild type cultures and induce nuclear localization of MTF-1.  A.)  2hr 
treatment with sublethal doses of the nitric oxide donor SNAP or the superoxide 
generator paraquat provide significant protection against 4hr oxygen-glucose deprivation 
72 hours following preconditioning.  * Significantly different from control (p < 0.05).  ** 
Significantly different from fresh SNAP (p < 0.05)  B.)  SNAP and paraquat, but not the 
degraded form of SNAP induce increased nuclear localization of MTF-1. C.)  
Semiquantitative analysis of nuclear MTF-1 levels from Western blots (percent above 
control ± SEM, n=3). 
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Figure 4.2.  Isoflurane preconditioning corresponds with increased MTF-1 
localization.  A.)  Preconditioning with isoflurane provided significant protection from 
4hr oxygen glucose deprivation in wild type-derived cultures.  Co-incubation with the 
inducible nitric oxide inhibitor, aminoguanidine,  diminished isoflurane mediated 
protection to non-significant levels.  The superoxide dismutase mimetic MnTBAP also 
diminished isoflurane mediated protection.  * Significantly different from control p < 
0.05.  **  Significantly different from isoflurane treatment alone (p< 0.05) B.)  2 hr 
isoflurane preconditioning increased nuclear levels of the metal-responsive transcription 
factor-1.  Aminoguanidine and MnTBAP, abrogated isoflurane-mediated increases in 
nuclear MTF-1.  C.)  Semi-quantitative nuclear MTF-1 levels from Western blots 
(percent above or below control ± SEM, n=3). 
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Figure 4.3.  Metallothionein I + II knockout abrogates protection from isoflurane, 
nitric oxide and superoxide preconditioning, but does not block MTF-1 
translocation.  A.)  Cultures from MT-I + II knockouts showed no significant protection 
from preconditioning with isoflurane, nitric oxide or superoxide.  B.)  Knockout of 
metallothioneins I + II attenuated nuclear translocation of MTF-1 in isoflurane, nitric 
oxide and superoxide treatment treated cultures. C.) Semi-quantitative nuclear MTF-1 
levels (percent above control ± SEM, n=3) from Western blots.  Wild-type data from 
Figures 4.1 B and 4.2 B are included for comparison with MTKO results. 
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Figure 4.4.  Simplified model for nitric oxide signaling involving metallothioneins.  
1.)  iNOS, eNOS or both activity increases in response to isoflurane treatment 
40,50,52,142,143
 2.)  Nitric oxide will combine with superoxide if it is present 11.  3.)  Nitric 
oxide122,128,144, superoxide and/or peroxynitrite146 react with metallothionein cysteines to 
form sulfhydryl groups. In the process, metallothionein conformation is changed such 
that it releases zinc ions146,147. 4.)  Metal responsive transcription factor-1 binds with zinc 
and translocates to the nucleus123,148.  This process may require and interaction with 
hypoxia-inducible factor 1149.  5.) Once in the nucleus, MTF-1 binds to metal response 
element, triggering the transcription of metallothionein I + II genes85.  6.)  APO 
metallothionein (aka thionein) in the cytoplasm will bind with labile zinc to form 
metallothionein and confers protection against OGD by a yet to be determined 
mechanism.This process may require and interaction with hypoxia-inducible factor 1149.  
5.) Once in the nucleus, MTF-1 binds to metal response element, triggering the 
transcription of metallothionein I + II genes85.  6.)  APO metallothionein (aka thionein) in 
the cytoplasm will bind with labile zinc to form metallothionein and confers protection 
against OGD by a yet to be determined mechanism. 
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CHAPTER 5 
FUTURE DIRECTIONS 
 
In the course of this dissertation, I was not able to address what may end up being one of 
the more interesting questions of the metallothionein/preconditioning story:  What is the 
mechanism by which metallothioneins are able to protect against ischemic injury?  The 
road to answer to this question will undoubtedly be interesting, but also challenging.  It 
has been ~50 years since Margoshes and Vallee isolated and Kagi and Vallee 
characterized metallothioneins derived from horse kidney that had been exposed to high 
levels of cadmium 155.  Since that time metallothioneins have been extensively studied, 
and despite thousands of studies, a definitive and comprehensive role for 
metallothioneins in either normal or pathological physiology has yet to emerge 156.  Yet, 
as reviewed by Penkowa 85, metallothioneins have been shown to participate in a number 
of processes involved with cellular protection in the brain.  Major biological roles for 
metallothioneins, as depicted in Figure 5.1, include modulation of inflammation, control 
of cellular oxidation levels, support of tissue repair and remodeling, angiogenesis, cell 
cycle and proliferation, and neuronal survival and plasticity 85.  And while the above roles 
are described for brain, metallothioneins I + II have also been shown to be protective in 
other tissues including heart 157, liver 158, kidney 112 and intestine 159, suggesting the 
possibility that preconditioning induced metallothioneins may play an important role in 
the protection of other tissues. 
 One of the more interesting questions in regards to metallothionein-mediated 
protection, especially in the brain, is the provenance of the metallothioneins that provide 
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protection.   While the vast majority of the literature describing metallothionein-mediated 
protection focuses on intracellular metallothioneins, there is a growing literature 
supporting a protective role for extracellular metallothioneins 82,85. Exogenous 
metallothioneins have been shown to reduce inflammation, inhibit apoptosis, and 
improve remyelination in experimental autoimune encephalomyelitis (EAE), an animal 
model of multiple sclerosis 91.   Furthermore, exogenous MT I + II administration was 
beneficial in an experimental model of traumatic brain injury 83.  The acute injuries 
sustained in the core of the traumatic lesion by the MT I + II –treated and control groups 
were largely the same.  However, in animals treated with subcutaneous MT I + II, the 
tissue surrounding the core lesion showed less oxidative stress, neurodegeneration and 
apoptotic cell death in the days and weeks that followed 83.  MT-I + II treatment also 
improved cellular repair, with increased expression of growth factors, improved 
astrogliosis, and angiogenesis 83.  Furthermore, the necrotic lesion cavity showed 
enhanced reorganization in MT treated subjects than in controls 83.  Recent work by 
Amborn et al., suggests a possible mechanism for exogenous metallothionein-mediated 
protection 82.  They found that extracellular metallothioneins interact with plasma 
membrane megalin receptors to trigger cellular protection through a signaling pathway 
that involved extracellular signal-regulated kinase, protein kinase B and c-AMP response 
element binding protein 82. Finally, they found exogenous metallothioneins inhibited  
apoptosis by reducing expression of the proapoptotoc B-cell leukemia/lymphoma-2 
interacting member of cell death (Bim(S)) 82.  In order to understand how 
metallothioneins are protective in the context of delayed anesthetic preconditioning, it 
will be important to determine where metallothioneins I + II are acting.  If 
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metallothioneins are acting intra-cellularly, then approaches to increase metallothionein 
expression might prove beneficial for prevention of ischemic injury in settings where 
there is a known risk.  On the other hand, since exogenous xenobiotic metallothioneins 
appear to be well-tolerated 160, the finding that extra-cellular metallothioneins can protect 
against ischemic injury would open the door to a range of potential treatment avenues 
including metallothioneins, metallothionein mimetics and so forth. 
 Other questions that will be interesting to pursue include, but are not limited to:  
1.) How does metallothionein’s role in zinc metabolism influence cellular signaling and 
protection 123,129,153,161,162?  Is it metallothionein or its modulation of available zinc, or 
both that determine protection 153?  2.)  How do metallothionein’s antioxidant 
characteristics contribute to preconditioning.  Do they act to simply detoxify existing 
oxidants, or do they act to inhibit the production of them in the first place 85,127?  3.)  Can 
exogenous metallothioneins be used to protect against ischemic injury both in vitro and in 
vivo?  Can synthetic MT mimetics be used to greater effect82? 4.) In the context of 
preconditioning, what is the role of metallothioneins in modulating inflammatory 
response 91? and 5.)  What role do metallothioneins I + II play in preconditioning-
mediated protection of other tissues? 
 In the work described above, we have established an important role for 
metallothioneins I + II in delayed anesthetic mediated protection against ischemic injury.  
In the years to come, there is much work to be done to better understand how 
metallothioneins act both on their own, and in concert with other molecules involved in 
preconditioning.  By improving this understanding of these processes, we hope to 
contribute to improved clinical outcomes for patient subject to ischemic injury. 
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Figure 5.1.  Summary of the major biological roles of metallothioneins I + II.  Figure 
modified from Penkowa 85 
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CHAPTER 6 
CONCLUSION 
 
 Delayed anesthetic preconditioning is a growing field of study for protection 
against ischemic injury due to its promise of a multi-pathway approach, multi-tissue 
protection and the relative safety of administration.  This dissertation described three 
projects aimed at furthering our knowledge of the mechanisms involved in phenomenon. 
In our first study, we hypothesized that, given the complexity of the ischemic 
cascade, it was likely that there were molecules and pathways involved in 
preconditioning that had not yet been identified.  Using DNA microarray we were able to 
identify genes that were differentially expressed in rat liver, kidney, and heart 90min 
following a clinical exposure to the commonly used volatile anesthetic, isoflurane.  Given 
that preconditioning has been reported in a wide range of tissues and organisms, we were 
able to combine and reduce the individual tissue lists to reflect those genes that were 
differentially regulated in more than one tissue and select for genes potentially involved 
in conserved endogenous protection pathways.  This combined approach yielded a list of 
34 genes that we subjected to a more in-depth literature review.  Using this approach we 
were able to identify a number of interesting genes for further study including 
metallothioneins I + II, basigin, and interferon regulatory factor 1. 
 For the second study, I selected metallothioneins I + II for further study, two 
genes that were both highly differentially regulated in multiple tissues and had literature 
support for potential as protective agents.  In this study we established the viability of 
using primary cultures in concert with oxygen-glucose deprivation to study delayed 
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anesthetic preconditioning.  From these experiments it was determined that our in vitro 
model displayed levels of protection and protection time-courses that were very similar to 
those reported for in vivo models.  Once the model was established, I was able to: 1.) 
establish a time-course for metallothionein I + II expression in response to isoflurane 
treatment, 2.)  show that both neurons and glia are protected during delayed APC and 3.) 
show that neurons were both more susceptible to oxygen-glucose deprivation toxicity and 
showed greater protection from preconditioning. 4.) establish, through the use of 
knockdown and knockout studies, that metallothioneins are integrally involved in 
isoflurane-mediated delayed protection and 5.) demonstrate through direct transfection of 
exogenous metallothionein protein that metallothioneins likely act as end effectors of 
protection against ischemic injury. 
Finally, in the third study, I addressed the mechanism of metallothionein action in 
the context of delayed preconditioning.  Dirnagl, in his 2008 review of delayed 
preconditioning, categorized molecules involved in preconditioning as being sensor, 
transducer, or effector molecules 91.  From our investigations in the second study, it 
seemed likely that metallothioneins act as effector molecules whose action is directly 
involved in protection.  Although the knockdown and knockout studies could arguably 
support any of these roles for metallothionein, the experiment in which cells were 
transfected  and protected by exogenous metallothionein immediately before OGD 
supports a likely role for MT I + II as an end effector.  The literature however, indicated 
another possible role for metallothioneins as  sensors of oxidative stress 123,128,129,161,163. In 
order to determine if metallothioneins I + II occupy this role in the context of delayed 
preconditioning, I correlated isoflurane, nitric oxide and superoxide-mediated protection 
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with the nuclear translocation of the metallothionein transcription factor MTF-1.  From 
these studies, I was able to determine that: 1.) blocking NO or .O2 production during APC 
decreased both protection and nuclear localized MTF-1.  2.) The NO and .O2 generators 
alone were sufficient to precondition mixed neuronal cultures and that this too, 
corresponded with increased nuclear localization of MTF-1.  3.) Finally, knockout of 
metallothionein I + II genes not only eliminated protection induced by NO and .O2  but 
also diminished preconditioning-mediated increases in nuclear MTF-1 levels.  Together, 
these data supported a role for metallothioneins I + II in delayed preconditioning as both 
sensors of oxidative stress and as end effectors of protection. 
In conclusion, the three studies described above contribute to our understanding 
of the mechanisms of delayed anesthetic preconditioning.  These studies, along with 
future experiments will lead to a better understanding of the mechanisms involved in 
endogenous protection and give us clues as to how to harness these pathways to provide 
improved clinical outcomes. 
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